<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-04-29T00:43:49Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8518950" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8518950</identifier>
        <datestamp>2021-10-21</datestamp>
        <setSpec>blackwellopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="jper10747" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Periodontol</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Periodontol</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)1943-3670</journal-id>
              <journal-id journal-id-type="publisher-id">JPER</journal-id>
              <journal-title-group>
                <journal-title>Journal of Periodontology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0022-3492</issn>
              <issn pub-type="epub">1943-3670</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8518950</article-id>
              <article-id pub-id-type="pmcid">PMC8518950</article-id>
              <article-id pub-id-type="pmc-uid">8518950</article-id>
              <article-id pub-id-type="pmid">33586783</article-id>
              <article-id pub-id-type="pmid">33586783</article-id>
              <article-id pub-id-type="doi">10.1002/JPER.20-0800</article-id>
              <article-id pub-id-type="publisher-id">JPER10747</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Human Randomized Controlled Trial</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Translational Periodontology</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Use of amnion‐derived cellular cytokine solution for the treatment of gingivitis: A 2‐week safety, dose‐ranging, proof‐of‐principle randomized trial</article-title>
                <alt-title alt-title-type="left-running-head">HASTURK et al.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="jper10747-cr-0001" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Hasturk</surname>
                    <given-names>Hatice</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4395-3958</contrib-id>
                  <xref rid="jper10747-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <address>
                    <email>hhasturk@forsyth.org</email>
                  </address>
                </contrib>
                <contrib id="jper10747-cr-0002" contrib-type="author">
                  <name>
                    <surname>Steed</surname>
                    <given-names>David</given-names>
                  </name>
                  <xref rid="jper10747-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jper10747-cr-0003" contrib-type="author">
                  <name>
                    <surname>Tosun</surname>
                    <given-names>Emre</given-names>
                  </name>
                  <xref rid="jper10747-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jper10747-cr-0004" contrib-type="author">
                  <name>
                    <surname>Martins</surname>
                    <given-names>Melissa</given-names>
                  </name>
                  <xref rid="jper10747-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jper10747-cr-0005" contrib-type="author">
                  <name>
                    <surname>Floros</surname>
                    <given-names>Constantinos</given-names>
                  </name>
                  <xref rid="jper10747-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jper10747-cr-0006" contrib-type="author">
                  <name>
                    <surname>Nguyen</surname>
                    <given-names>Daniel</given-names>
                  </name>
                  <xref rid="jper10747-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jper10747-cr-0007" contrib-type="author">
                  <name>
                    <surname>Stephens</surname>
                    <given-names>Danielle</given-names>
                  </name>
                  <xref rid="jper10747-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jper10747-cr-0008" contrib-type="author">
                  <name>
                    <surname>Cugini</surname>
                    <given-names>Maryann</given-names>
                  </name>
                  <xref rid="jper10747-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jper10747-cr-0009" contrib-type="author">
                  <name>
                    <surname>Starr</surname>
                    <given-names>Jacqueline</given-names>
                  </name>
                  <xref rid="jper10747-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jper10747-cr-0010" contrib-type="author">
                  <name>
                    <surname>Van Dyke</surname>
                    <given-names>Thomas E.</given-names>
                  </name>
                  <xref rid="jper10747-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="jper10747-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">The Forsyth Institute</named-content>
                <institution>Center for Clinical and Translational Research</institution>
                <city>Cambridge</city>
                <named-content content-type="country-part">MA</named-content>
              </aff>
              <aff id="jper10747-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <institution>Noveome Biotherapeutics</institution>
                <city>Pittsburgh</city>
                <named-content content-type="country-part">PA</named-content>
              </aff>
              <aff id="jper10747-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Brigham and Women's Hospital</named-content>
                <institution>Channing Division of Network Medicine</institution>
                <city>Boston</city>
                <named-content content-type="country-part">MA</named-content>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Hatice Hasturk, The Forsyth Institute, Cambridge, MA 02142<break/>Email: <email>hhasturk@forsyth.org</email><break/></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>06</day>
                <month>5</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>9</month>
                <year>2021</year>
              </pub-date>
              <volume>92</volume>
              <issue seq="130">9</issue>
              <issue-id pub-id-type="doi">10.1002/jper.v92.9</issue-id>
              <fpage>1317</fpage>
              <lpage>1328</lpage>
              <history>
                <date date-type="rev-recd">
                  <day>02</day>
                  <month>2</month>
                  <year>2021</year>
                </date>
                <date date-type="received">
                  <day>06</day>
                  <month>11</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>03</day>
                  <month>2</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <!--&#x000a9; 2021 American Academy of Periodontology-->
                <copyright-statement content-type="article-copyright">© 2021 The Authors. <italic toggle="yes">Journal of Periodontology</italic> published by Wiley Periodicals LLC on behalf of American Academy of Periodontology</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:JPER-92-1317.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="jper10747-sec-0010">
                  <title>Background</title>
                  <p>A 6‐week Phase I clinical trial was performed to primarily evaluate the safety and secondarily determine the preliminary efficacy of a novel biological solution, ST266, comprised of a mixture of cytokines, growth factors, nucleic acids, and lipids secreted by cultured amnion‐derived multipotent progenitor cells on gingival inflammation.</p>
                </sec>
                <sec id="jper10747-sec-0020">
                  <title>Methods</title>
                  <p>Fifty‐four adults with gingivitis/periodontitis were randomly assigned to 1X ST266 or diluted 0.3X ST266 or saline topically applied on facial/lingual gingiva (20 µL/tooth). Safety was assessed through oral soft/hard tissue exam, adverse events, and routine laboratory tests. Efficacy was assessed by modified gingival index (MGI), bleeding on probing, plaque index, probing depth (PD), and clinical attachment level (CAL). Assessments were performed on day 0, 8, 12, and 42. ST266 and saline applied daily starting at day 0 through day 12 except weekend days. Plasma was analyzed for safety and proinflammatory cytokines, interleukin (IL)‐1β, IL‐6, tumor necrosis factor‐alpha, and interferon gamma. Gingival crevicular fluid (GCF) was analyzed for the same cytokines. Subgingival plaque was primarily analyzed by checkerboard DNA‐DNA hybridization. Comparisons with saline were modeled through a generalized estimating equations method adjusting for baseline.</p>
                </sec>
                <sec id="jper10747-sec-0030">
                  <title>Results</title>
                  <p>No safety concern was found related to ST266. Statistically significant reduction in MGI was noted at day 42 by 1X ST266 compared with saline (<italic toggle="yes">P</italic> = 0.044). PD and CAL were reduced by both doses of ST266 at day 42 (<italic toggle="yes">P</italic> &lt;0.01) and by 1X ST266 at day 12 (<italic toggle="yes">P</italic> &lt;0.05). GCF IL‐1β and IL‐6 levels were reduced by both doses of ST266 at day 12 (<italic toggle="yes">P</italic> &lt;0.05, <italic toggle="yes">P</italic> &lt;0.01, respectively). IL‐6 was also significantly reduced in plasma of both ST266 groups (<italic toggle="yes">P</italic> &lt;0.05). Significant reductions in red complex bacteria were detected in both ST266 doses.</p>
                </sec>
                <sec id="jper10747-sec-0040">
                  <title>Conclusions</title>
                  <p>In this “first in human oral cavity” study, topical ST266 was safe and effective in reducing gingival inflammation in 6 weeks. Longitudinal studies with large sample sizes are warranted to assess the therapeutic value of this novel host modulatory compound in the treatment of periodontal diseases.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="jper10747-kwd-0001">cytokines</kwd>
                <kwd id="jper10747-kwd-0002">gingival crevicular fluid</kwd>
                <kwd id="jper10747-kwd-0003">gingivitis</kwd>
                <kwd id="jper10747-kwd-0004">host modulation</kwd>
                <kwd id="jper10747-kwd-0005">inflammation</kwd>
                <kwd id="jper10747-kwd-0006">periodontal disease</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>Noveome Biotherapeutics</funding-source>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="3"/>
                <table-count count="3"/>
                <page-count count="12"/>
                <word-count count="7711"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>September 2021</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.0.8 mode:remove_FC converted:15.10.2021</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="jper10747-cit-0048"><string-name><surname>Hasturk</surname><given-names>H</given-names></string-name>, <string-name><surname>Steed</surname><given-names>D</given-names></string-name>, <string-name><surname>Tosun</surname><given-names>E</given-names></string-name>, et al. <article-title>Use of amnion‐derived cellular cytokine solution for the treatment of gingivitis: A 2‐week safety, dose‐ranging, proof‐of‐principle randomized trial</article-title>. <italic toggle="yes">J Periodontol</italic>. <year>2021</year>;<volume>92</volume>:<fpage>1317</fpage>–<lpage>1328</lpage>. <pub-id pub-id-type="doi">10.1002/JPER.20-0800</pub-id>.</mixed-citation>
              </p>
            </notes>
          </front>
          <body>
            <sec id="jper10747-sec-0050">
              <label>1</label>
              <title>INTRODUCTION</title>
              <p>Periodontal disease affects millions of Americans and adequate, long‐term, stable therapy remains a clinical problem with an economic burden.<xref rid="jper10747-bib-0001" ref-type="bibr"><sup>1</sup></xref> In periodontitis, an acute inflammatory reaction to commensal bacteria leads to inflammation and dysbiosis of the local microbiome.<xref rid="jper10747-bib-0002" ref-type="bibr"><sup>2</sup></xref> If acute inflammation is not resolved and becomes chronic, there is innate and acquired immune pathway‐mediated tissue destruction that leads to tooth loss.<xref rid="jper10747-bib-0003" ref-type="bibr"><sup>3</sup></xref> Although infection by Gram‐negative bacteria such as <italic toggle="yes">Porphyromonas gingivalis</italic> is considered to be the primary etiologic factor in periodontal disease, the cause‐and‐effect relationship between the pathogen and disease is not clear.<xref rid="jper10747-bib-0004" ref-type="bibr"><sup>4</sup></xref> What is clear, however, is that a dysbiotic biofilm develops and if left unchecked, the periodontium including periodontal ligament and bone are destroyed. Mechanical debridement for biofilm removal has long been the standard prevention and treatment for gingivitis and periodontitis.<xref rid="jper10747-bib-0005" ref-type="bibr"><sup>5</sup></xref> However, plaque removal is a short‐term method for reducing inflammation; levels of biofilm bacteria rebound even in higher amounts after mechanical therapy in the absence of further treatment or maintenance which leads to a rapid return of the disease‐associated hyper‐inflammation.<xref rid="jper10747-bib-0006" ref-type="bibr"><sup>6</sup></xref> Despite there being anti‐bacterial and anti‐plaque agents, only a few drugs/compounds are available to target the inflammatory response directly without significant side effects. To reduce the inflammatory response in tissues, drugs such as non‐steroidal inflammatory agents have been used with limited clinical benefits and with a significant risk of unwanted side effects.<xref rid="jper10747-bib-0007" ref-type="bibr"><sup>7</sup></xref> Similarly, systemic or local antibiotic therapy may provide a short‐term benefit without a long‐term solution and their use raises significant concerns due to increasing risk of antibiotic resistance.<xref rid="jper10747-bib-0008" ref-type="bibr"><sup>8</sup></xref> New agents that stimulate the active resolution of inflammation may offer some therapeutic advantage in the treatment of periodontitis compared with more traditional pharmacologic interventions.<xref rid="jper10747-bib-0009" ref-type="bibr"><sup>9</sup></xref>
</p>
              <p>Amnion‐derived multipotent progenitor (AMP) cells produced by proprietary culturing of amnion epithelial cells obtained from non‐controversial, donated full‐term placentas, secrete a unique cocktail of cytokines at physiological levels.<xref rid="jper10747-bib-0010" ref-type="bibr"><sup>10</sup></xref> The cells are non‐tumorigenic and non‐immunogenic, unlike other stem cells.<xref rid="jper10747-bib-0011" ref-type="bibr"><sup>11</sup></xref> The cytokine secretome, referred to as ST266 (previously termed amnion‐derived cellular cytokine solution or ACCS), tested in a variety of animal models,<xref rid="jper10747-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="jper10747-bib-0013" ref-type="bibr"><sup>13</sup></xref>, <xref rid="jper10747-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="jper10747-bib-0015" ref-type="bibr"><sup>15</sup></xref> accelerates and improves wound healing in both acute and chronic infected wounds regardless of change in bacterial bioburden.<xref rid="jper10747-bib-0013" ref-type="bibr"><sup>13</sup></xref>, <xref rid="jper10747-bib-0016" ref-type="bibr"><sup>16</sup></xref> In addition, ST266 is effective in the prevention and treatment of periodontitis in animal models.<xref rid="jper10747-bib-0017" ref-type="bibr"><sup>17</sup></xref>, <xref rid="jper10747-bib-0018" ref-type="bibr"><sup>18</sup></xref> In rabbit periodontitis, ST266 reduces inflammation and promotes healing and tissue regeneration.<xref rid="jper10747-bib-0018" ref-type="bibr"><sup>18</sup></xref> In acute and chronic wound models,<xref rid="jper10747-bib-0013" ref-type="bibr"><sup>13</sup></xref> skin grafting in rats<xref rid="jper10747-bib-0014" ref-type="bibr"><sup>14</sup></xref> and in diabetic wound model in pigs,<xref rid="jper10747-bib-0012" ref-type="bibr"><sup>12</sup></xref> it improves healing by accelerating wound closure and epithelization kinetics, promoting migration of keratinocytes and fibroblasts and increasing number of epidermal cell layers and rete ridges. ST266 promotes macrophage activity including increased phagocytosis and bactericidal activity.<xref rid="jper10747-bib-0019" ref-type="bibr"><sup>19</sup></xref> Recently, treatment with ST266 ameliorated neuroinflammation in a rat model of brain injury and resulted in retinal ganglion cell neuroprotection in experimental optic neuropathies.<xref rid="jper10747-bib-0020" ref-type="bibr"><sup>20</sup></xref>, <xref rid="jper10747-bib-0021" ref-type="bibr"><sup>21</sup></xref> In a Phase I safety trial, topical application of ST266 in patients receiving breast radiotherapy was found safe in both intact and denuded, irradiated skin without systemic absorption.<xref rid="jper10747-bib-0022" ref-type="bibr"><sup>22</sup></xref> In a Phase II clinical trial, topical ST266 was shown to reduce the acute effects of UV light‐induced skin damage while reducing erythema and increasing DNA repair protein with decreased damaged DNA.<xref rid="jper10747-bib-0023" ref-type="bibr"><sup>23</sup></xref>
</p>
              <p>Based on these safety data and the previous in vitro and in vivo findings in rabbit periodontitis, a Phase I randomized controlled clinical trial was designed to assess the safety and the preliminary efficacy of intra‐oral topical application of two doses of ST266 in the reduction of gingival inflammation in patients with existing gingivitis/periodontitis.</p>
            </sec>
            <sec id="jper10747-sec-0060">
              <label>2</label>
              <title>MATERIALS AND METHODS</title>
              <sec id="jper10747-sec-0070">
                <label>2.1</label>
                <title>Ethical considerations and subject population</title>
                <p>The study protocol was approved by the Forsyth Institute Institutional Review Board before initiation (Protocol #14‐01) and conducted in accordance with the Helsinki Declaration of 1975, as revised in 2013. All subjects provided written informed consent before screening and enrollment procedures. The study was registered at ClinicalTrials.gov (NCT02071199).</p>
                <p>Participants were recruited at the Center for Clinical and Translational Research (CCTR) clinic at the Forsyth Institute in Cambridge, Massachusetts. Individuals with good general health who consented to take part in the clinical trial, with an age range of 18 to 70 years, having at least 20 natural teeth excluding third molars, a whole mouth mean MGI score of ≥2 and at least 40% bleeding sites at initial presentation were enrolled in the study between April 2014 and June 2015.</p>
                <p>Those with current medical conditions or on medications known to affect periodontal tissues or interfere with any of the study outcomes and those with history of cancer or any chronic infectious diseases were excluded. In addition, individuals with orthodontic appliances, pregnant and nursing women, and current or former smokers within 1 year of enrollment were excluded. Eligible subjects who met the inclusion/exclusion criteria were enrolled.</p>
              </sec>
              <sec id="jper10747-sec-0080">
                <label>2.2</label>
                <title>Study design</title>
                <p>This Phase 1 study was designed as a dose‐escalating, randomized, prospective, double‐blind parallel group clinical study to primarily test the safety and, secondarily, preliminary clinical efficacy of two concentrations of ST266 on gingivitis compared with saline as control. Study participants (n = 27) assigned to the first cohort received 0.3X ST266 (n = 18) or saline (n = 9) in a 2:1 (ST266:saline) randomization scheme. Study medication (20 µL/tooth, &lt;1 mL/day) was topically applied to each tooth at the gingival margin by a calibrated pipette. The dose was chosen based on the preclinical animal data, filed in the original submission of the Investigational New Drug (IND) application, which demonstrated clinically significant difference compared with placebo in experimental periodontitis.<xref rid="jper10747-bib-0018" ref-type="bibr"><sup>18</sup></xref> The frequency (daily) and duration of the treatment (2 weeks‐total of 10 treatments) was based on the previous reports on topical use of ST266 in wound healing where bacterial bioburden was taken into consideration<xref rid="jper10747-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="jper10747-bib-0016" ref-type="bibr"><sup>16</sup></xref> After completion of treatment in the first cohort and upon receipt of a satisfactory unmasked safety review by the Data and Safety Monitoring Board, the separate second cohort (n = 27) received 1X ST266 (n = 18) or saline (n = 9) in the same randomization scheme of 2:1 (ST266:saline) (See Table <xref rid="jper10747-supitem-0003" ref-type="supplementary-material">S1</xref> in online <italic toggle="yes">Journal of Periodontology</italic>). The subjects received 10 consecutive daily treatments over 2 weeks (except the weekend days), administered at Forsyth by a periodontist (HH) masked to the randomization scheme. Clinical assessments included safety and efficacy measurements performed at baseline, on day 8, at the end of the treatment phase (day 12) and at day 42 after the last treatment. An oral hygiene questionnaire was used to obtain current oral hygiene habits at baseline. All participants were given instructions for twice daily brushing with their regular manual toothbrush and a fluoride toothpaste, and not to change to another brand during the study. They were also instructed to stop using mouthwashes and chewing gums during the course of the study. Participants were provided a full‐mouth professional tooth cleaning at the end of the study and referred to further periodontal treatment if deemed necessary.</p>
              </sec>
              <sec id="jper10747-sec-0090">
                <label>2.3</label>
                <title>Primary outcome measure</title>
                <p>Safety was the primary outcome measure and was monitored by evaluation of all adverse event/severe adverse event (AE/SAE) reports, subjects medical/medication history, concomitant medication reports, subject conduct/compliance, soft and hard tissue evaluations at every visit (daily) and dropout rates. Serum chemistry including C‐reactive protein (CRP), liver and kidney function tests, complete blood count, urinalysis and, in women of childbearing potential, a pregnancy test was performed before enrollment and repeated upon completion of treatment on day 12.</p>
                <p>To detect any adverse shifts in the supragingival microflora, plaque samples from six teeth (Ramfjord teeth) were collected, pooled and analyzed using DNA‐DNA (checkerboard) hybridization<xref rid="jper10747-bib-0024" ref-type="bibr"><sup>24</sup></xref> to provide a qualitative and semi‐quantitative assessment of 13 oral bacteria, including <italic toggle="yes">Fusobacterium nucleatum ss.vincentii, Campylobacter concisus, Campylobacter rectus, Bacteriodes forsythus, Porphyromonas gingivalis, Prevotella intermedia, Prevotella nigrescens, Capnocytophaga sputigena, Streptococcus oralis, Actinomyces naeslundii, Treponema denticola, Campylobacter curva, and Eikenella corrodens</italic>. Results were compared with known probe standards and scored on an ordinal scale of 0 to 5 as previously reported.<xref rid="jper10747-bib-0025" ref-type="bibr"><sup>25</sup></xref>
</p>
                <p>To determine the systemic exposure of locally delivered ST266, peripheral blood samples were collected via venipuncture before and 1 h after the first topical treatment at day 0 and after the final treatment session on day 12. Plasma was separated, aliquoted, and stored at ‐80°C until analysis. Plasma levels of nine proteins known to be in ST266 were measured for the following analytes: platelet‐derived growth factor, vascular endothelial growth factor, angiogenin, tissue inhibitor of matrix metalloprotease‐1 (TIMP‐1) and 2 (TIMP‐2), carcinoembryonic antigen‐125 (CA‐125), decorin, matrix metalloprotease‐9, and epidermal growth factor. Plasma samples were prepared and diluted according to the manufacturer's recommendations and run using a multiarray next generation of ELISA platform<xref rid="jper10747-note-0001" ref-type="fn">*</xref> and read on an image analyzer<xref rid="jper10747-note-0002" ref-type="fn">†</xref>. The concentrations were determined by comparison with a standard curve of recombinant protein. One of the aliquots of plasma was stored for proinflammatory cytokine analysis (a secondary outcome measure) at the Forsyth Institute Luminex Core as described below.</p>
              </sec>
              <sec id="jper10747-sec-0100">
                <label>2.4</label>
                <title>Secondary outcome measures</title>
                <sec id="jper10747-sec-0110">
                  <label>2.4.1</label>
                  <title>Clinical periodontal measurements</title>
                  <p>Preliminary efficacy was evaluated at baseline and day 8, 12, and 42 using multiple parameters, including modified gingival index (MGI)<xref rid="jper10747-bib-0026" ref-type="bibr"><sup>26</sup></xref> at six sites per tooth (mesiobuccal, buccal, distobuccal, distolingual, lingual, and mesiolingual). Bleeding on probing (BOP) assessed as a dichotomous score of 0 or 1 after probing measurements were performed independently of the gingival index measurement and considered as the secondary gingivitis outcome variable. Amount of plaque on tooth surfaces was assessed using the Turesky Modification of Quigley‐Hein Plaque Index (PI)<xref rid="jper10747-bib-0027" ref-type="bibr"><sup>27</sup></xref> at six sites of the tooth. Probing depth (PD) and clinical attachment level (CAL) were measured using a UNC‐15 periodontal probe<xref rid="jper10747-note-0003" ref-type="fn">‡</xref>at six sites per tooth.</p>
                </sec>
              </sec>
              <sec id="jper10747-sec-0120">
                <label>2.5</label>
                <title>Examiner calibration</title>
                <p>A single examiner (MM) masked to treatment allocations and not involved in topical treatments was responsible for all clinical oral measurements in a given subject for the course of the study. An intra‐examiner calibration exercise was performed as previously described<xref rid="jper10747-bib-0028" ref-type="bibr"><sup>28</sup></xref> with a minimum κ coefficient of 0.8.</p>
              </sec>
              <sec id="jper10747-sec-0130">
                <label>2.6</label>
                <title>Proinflammatory cytokines</title>
                <p>Changes in proinflammatory cytokines in the GCF and blood plasma were determined as an exploratory outcome measure. Gingival crevicular fluid (GCF) and peripheral blood plasma samples were obtained during the study to determine the changes in local and systemic levels of proinflammatory cytokines, respectively. GCF samples were collected at day 0, day 12, and day 42 from the most inflamed mesiobuccal sites of four teeth, one per quadrant based on MGI score (highest MGI score), using sterile PerioPaper strips<xref rid="jper10747-note-0004" ref-type="fn">§</xref> for 30 seconds. Following collection, the samples were snap‐frozen in liquid nitrogen and stored at ‐80°C until analysis.</p>
                <p>On the day of analysis, the frozen GCF samples were thawed at room temperature and proteins were eluted through two centrifugations at 13,000 × g at 4°C for 8 minutes in a total of 120‐µL sterile phosphate buffered saline (PBS, pH 7.4). In all analyses, 100 µL of eluted solution was used. In parallel, plasma samples were also thawed at room temperature and 1:2 dilutions prepared. Both the GCF and plasma samples were analyzed for proinflammatory cytokines including interleukin (IL)‐1β, IL‐6, tumor necrosis factor alpha (TNF‐α), and interferon gamma (IFN‐γ) using a 4 plex human high sensitivity cytokine panel<xref rid="jper10747-note-0005" ref-type="fn">¶</xref> by multiplexed sandwich immunoassays, based on flowmetric multiplex technology<xref rid="jper10747-note-0006" ref-type="fn">#</xref> at the Forsyth Institute Luminex Core as described previously.<xref rid="jper10747-bib-0029" ref-type="bibr"><sup>29</sup></xref> Briefly, assays were carried out on a flowmetric multiplex machine<sup>†</sup> and data were read using the image reader.<xref rid="jper10747-note-0007" ref-type="fn">**</xref> Immediately before the initiation of study measurements, the multiplex platform underwent a complete on‐site maintenance cycle and operationally qualified by the manufacturer's field engineers. Daily and weekly performance qualification was continuously verified by the Core staff during the analytical period. Assay analysis was performed according to manufacturer's protocols. Single lot numbers of each kit were used to minimize analytical variability. Reagents provided in these kits included magnetic beads pre‐coated with capture antibodies, standards, assay diluents, biotin‐conjugated secondary antibodies, biotin diluent, streptavidin conjugated to the fluorescent protein, R‐phycoerythrin (streptavidin‐RPE), streptavidin‐RPE diluent, washing buffer concentrates, and assay buffers, as well as the 96‐well filter or magnetic plates. The quality control measurements and coefficient variations were calculated as described previously by the same laboratory.<xref rid="jper10747-bib-0029" ref-type="bibr"><sup>29</sup></xref> The detection limits of the kits were 0.146 pg/mL for IL‐1β, 0.14 pg/mL for IL‐6, 0.29 pg/mL for TNF‐α, and 0.25 pg/mL for IFN‐γ.</p>
              </sec>
              <sec id="jper10747-sec-0140">
                <label>2.7</label>
                <title>Investigational product</title>
                <p>ST266 is a complex mixture of proteins, including cytokines and growth factors, nucleic acids, and lipids produced by cultured AMP cells. ST266 final drug product, lot number, E2751301, was aseptically filled and packaged<xref rid="jper10747-note-0008" ref-type="fn">††</xref> from bulk drug substance produced at Good Manufacturing Procedures facilities.<xref rid="jper10747-note-0009" ref-type="fn">‡‡</xref> Saline was used as the placebo.</p>
              </sec>
              <sec id="jper10747-sec-0150">
                <label>2.8</label>
                <title>Treatment compliance and data quality</title>
                <p>Treatment applications were performed in the dental clinic by the study investigator; therefore, non‐compliance was assessed based on the treatment visits missed. Data quality was monitored during monitoring visits by an external clinical research associate at regular intervals for the duration of the trial.</p>
              </sec>
              <sec id="jper10747-sec-0160">
                <label>2.9</label>
                <title>Statistical analysis</title>
                <sec id="jper10747-sec-0170">
                  <label>2.9.1</label>
                  <title>Power analysis</title>
                  <p>As the primary efficacy measure, modified gingival index was used to calculate sample size. Based on published studies, a sample size of 18 subjects per group (assuming a dropout rate of 20%) was calculated, using a generalized estimating equations (GEE) model for repeated measurements with an SD of 0.3 MGI units, 0.05 significance level; power of 80%; and exchangeable correlation structure with a correlation coefficient of ρ = 0.3 among repeated measurements. Fourteen (14) subjects in each group were needed to detect a difference of 0.2 units (mean MGI change). To compensate for attrition, assuming a 20% drop rate, 18 subjects per treatment group were enrolled in the study.</p>
                </sec>
                <sec id="jper10747-sec-0180">
                  <label>2.9.2</label>
                  <title>Statistics</title>
                  <p>Safety parameters compared across treatments (1X ST266 versus placebo and 0.3X ST266 versus placebo) included adverse events, vital signs, and oral cavity examination using GEE modeling. The fit of the linear regression models was done by using a GEE approach, estimating the temporal trend in each vital sign over the sequence of visits, by group. A fit of interaction term (visit*treatment) was done for each of the two dose groups. The temporal trend is an estimate of the average per day change in the vital sign. The interactions allow for estimation and testing of whether the temporal trend (rate of change) over the visits is different by treatment group. Other safety end points included blood chemistry, hematology, urinalysis, and levels of CRP before treatment (day 0) and on day 12. Tests on day 12 were repeated if any out of value was deemed clinically significant as confirmed by the medical monitor. For each of the four (4) end points, the number of values out of the normal range (0, 1, 2, 3, 4, &gt;4) at each time point was recorded. The repeat day 12 report was used if performed. The number and frequency of subjects with each number of abnormal values for each analysis and both time points were tabulated.</p>
                  <p>To detect any adverse shifts in the supragingival microflora, plaque samples from six teeth were collected pooled and analyzed using DNA‐DNA hybridization checkerboard. Values were then log<sub>10</sub>‐transformed. We used linear regression with robust standard errors to compare mean differences between each treatment group versus the placebo group.</p>
                  <p>Analysis of the efficacy data consisted of modeling end points, including MGI, BOP, PD, CAL, and PI with groups as the main effect adjusted for baseline. Treatment comparisons at post baseline were modeled through GEE (with a linear link, exchangeable covariance matrix, and robust variance) adjusting for the baseline value. GEE is an approach that accounts for repeated measures (i.e., multiple sites within each subject's mouth). Proinflammatory cytokine levels in GCF and in plasma were also analyzed using GEE modeling.</p>
                  <p>In secondary analyses, the rate of change over time was estimated with GEE analyses. The model included time (in days), treatment group indicators (with placebo as the reference group), and multiplicative interactions of each treatment indicator multiplied by time. The average rate of change per day is reported in each treatment group, and the differences in these rates of change for each treatment group (versus placebo). In the case of missing visits, the data were computed based on the number of treatments the subject received (minimum three treatment visits out of five completed at each week). All analyses were performed using a commercially available statistical package.<xref rid="jper10747-note-0010" ref-type="fn">§§</xref>
</p>
                </sec>
              </sec>
            </sec>
            <sec id="jper10747-sec-0190">
              <label>3</label>
              <title>RESULTS</title>
              <sec id="jper10747-sec-0200">
                <label>3.1</label>
                <title>Study participants</title>
                <p>Out of 196 subjects screened according to inclusion and exclusion criteria of the study, 63 subjects were found to be eligible and scheduled for a baseline visit. Five subjects dropped out before the baseline visit (four withdrew consent because of unavailability and one was lost to follow‐up). Of 58 subjects who came for the baseline visit, four subjects were terminated at baseline before randomization and treatment; one subject withdrew consent, one was non‐compliant, and two subjects were ineligible based on the inclusion criterion (&lt;40% BOP) (see Figure <xref rid="jper10747-supitem-0001" ref-type="supplementary-material">S1</xref> in online <italic toggle="yes">Journal of Periodontology</italic>). The remaining 54 subjects randomized into one of the study treatments completed the entire study participation and the safety and efficacy data obtained were included in the data analyses. All participants responded to questionnaire with at least once daily brushing, flossing at least 3 times/week, 21% were using mouthwashes and none were using irrigation devices (data not shown). During the study all participants continued using their regular manual toothbrush and a fluoride toothpaste twice a day and discontinued using mouthwashes. Approximately 33% (n = 18; 7 in placebo, 6 in 0.3x ST266; 5 in 1x ST266) of study population presented with localized periodontitis with PD 5 to 9 mm at ≤4 interproximal sites (see Table <xref rid="jper10747-supitem-0004" ref-type="supplementary-material">S2</xref> in online <italic toggle="yes">Journal of Periodontology</italic>).</p>
              </sec>
              <sec id="jper10747-sec-0210">
                <label>3.2</label>
                <title>ST266 is safe, well tolerated, and reduces red‐complex periodontal pathogens</title>
                <sec id="jper10747-sec-0220">
                  <label>3.2.1</label>
                  <title>Adverse events (AEs)</title>
                  <p>There were 124 reported events and oral cavity exam findings. All 124 events were categorized as mild; 3 (2.4%) were categorized as related, 5 (4%) were categorized as possibly related, and 5 (4%) were categorized as unlikely related (see Table <xref rid="jper10747-supitem-0005" ref-type="supplementary-material">S3</xref> in online <italic toggle="yes">Journal of Periodontology</italic>). All related and possibly related events were reported by the same two subjects who were assigned to placebo. All events were resolved regardless of study group. There were no AEs related to drug and no pattern of concern in the AEs reported. There were no serious AEs.</p>
                </sec>
                <sec id="jper10747-sec-0230">
                  <label>3.2.2</label>
                  <title>Vital signs</title>
                  <p>For all vital sign safety end points, except temperature, there were relatively few readings outside the normal range and no lasting pattern by treatment group or over time (see Table <xref rid="jper10747-supitem-0006" ref-type="supplementary-material">S4</xref> in online <italic toggle="yes">Journal of Periodontology</italic>). The temperatures outside the normal range were generally low and could have been affected by fluid intake before oral measurement.</p>
                  <p>Although there were minor differences in some of the vital sign measures by treatment group on day 1, there was no evidence that over the course of treatment the temporal trends in vital signs were different by treatment group.</p>
                </sec>
                <sec id="jper10747-sec-0240">
                  <label>3.2.3</label>
                  <title>Microbial analysis</title>
                  <p>Microbial analysis conducted primarily for safety of topical ST266 application showed no adverse shifts (increases in pathogenic bacteria) in the microflora (see Table <xref rid="jper10747-supitem-0007" ref-type="supplementary-material">S5</xref> in online <italic toggle="yes">Journal of Periodontology</italic>). On the contrary, the bacterial counts at day 10 showed reductions in red and orange complex bacteria known to be highly associated with periodontal disease (e.g., increased PD and BOP) compared with baseline counts in both ST266‐treated groups (Fig. <xref rid="jper10747-fig-0002" ref-type="fig">2</xref> and see Figure <xref rid="jper10747-supitem-0002" ref-type="supplementary-material">S2</xref> in online <italic toggle="yes">Journal of Periodontology</italic>).</p>
                </sec>
                <sec id="jper10747-sec-0250">
                  <label>3.2.4</label>
                  <title>Measurement of ST266 cytokines in plasma</title>
                  <p>Baseline protein levels varied slightly among groups. Local administration of ST266 in either dose did not increase protein levels measured 1 hour after the first or tenth dose of ST266 application.</p>
                </sec>
              </sec>
              <sec id="jper10747-sec-0260">
                <label>3.3</label>
                <title>ST266 reduces gingival inflammation and local proinflammatory cytokines</title>
                <sec id="jper10747-sec-0270">
                  <label>3.3.1</label>
                  <title>Clinical periodontal outcomes</title>
                  <p>Gingival index, BOP, PD, and CAL decreased over time with the treatment of both doses of ST266 at all time‐points; day 8, 12, and 42 and changes from baseline were greater compared with placebo (analysis adjusted for baseline differences) (Table <xref rid="jper10747-tbl-0001" ref-type="table">1</xref>). The change in primary end point MGI at day 42 with 1X ST266 reached statistical significance when compared with placebo (difference 0.1; <italic toggle="yes">P</italic> = 0.044; Fig. <xref rid="jper10747-fig-0001" ref-type="fig">1</xref>). Change in BOP approached statistical significance at day 8 with both doses of ST266 compared with placebo (<italic toggle="yes">P</italic> = 0.05, and <italic toggle="yes">P</italic> = 0.06, respectively). In formal analyses of mediation, this change in modified gingival index accounted for a modest but statistically significant proportion of the effect of ST266 treatment on the likelihood of BOP reduction calculated as odds of bleeding (mean decrease by the treatment: 14%; 95% confidence interval, 3%–35%; Table <xref rid="jper10747-tbl-0002" ref-type="table">2</xref>). No statistically significant differences were found in PI at any time point (Table <xref rid="jper10747-tbl-0001" ref-type="table">1</xref>).</p>
                  <table-wrap position="float" id="jper10747-tbl-0001" content-type="TABLE">
                    <label>TABLE 1</label>
                    <caption>
                      <p>Clinical outcomes: gingival index, bleeding on probing, and plaque index</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <col align="left" span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1"/>
                          <th style="border-bottom:solid 1px #000000" align="left" colspan="4" rowspan="1">Mean gingival index (MGI unit)</th>
                          <th style="border-bottom:solid 1px #000000" align="left" colspan="4" rowspan="1">Bleeding on probing (% of sites)</th>
                          <th style="border-bottom:solid 1px #000000" align="left" colspan="4" rowspan="1">Plaque index (PI unit)</th>
                        </tr>
                        <tr>
                          <th align="left" rowspan="1" colspan="1"/>
                          <th align="char" rowspan="1" colspan="1"/>
                          <th style="border-bottom:solid 1px #000000" align="left" colspan="2" rowspan="1">95% CI</th>
                          <th align="char" rowspan="1" colspan="1"/>
                          <th align="char" rowspan="1" colspan="1"/>
                          <th style="border-bottom:solid 1px #000000" align="left" colspan="2" rowspan="1">95% CI</th>
                          <th align="char" rowspan="1" colspan="1"/>
                          <th align="char" rowspan="1" colspan="1"/>
                          <th style="border-bottom:solid 1px #000000" align="left" colspan="2" rowspan="1">95% CI</th>
                          <th align="char" rowspan="1" colspan="1"/>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000" valign="bottom">
                          <th align="left" valign="bottom" rowspan="1" colspan="1">Time point and comparison</th>
                          <th align="left" valign="bottom" rowspan="1" colspan="1">Mean diff.</th>
                          <th align="left" valign="bottom" rowspan="1" colspan="1">Lower</th>
                          <th align="left" valign="bottom" rowspan="1" colspan="1">Upper</th>
                          <th align="left" valign="bottom" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th>
                          <th align="left" valign="bottom" rowspan="1" colspan="1">Mean diff.</th>
                          <th align="left" valign="bottom" rowspan="1" colspan="1">Lower</th>
                          <th align="left" valign="bottom" rowspan="1" colspan="1">Upper</th>
                          <th align="left" valign="bottom" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th>
                          <th align="left" valign="bottom" rowspan="1" colspan="1">Mean diff.</th>
                          <th align="left" valign="bottom" rowspan="1" colspan="1">Lower</th>
                          <th align="left" valign="bottom" rowspan="1" colspan="1">Upper</th>
                          <th align="left" valign="bottom" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td colspan="13" align="left" rowspan="1">8 days</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">0.3X ST266 minus placebo</td>
                          <td align="char" rowspan="1" colspan="1">−0.04</td>
                          <td align="char" rowspan="1" colspan="1">−0.13</td>
                          <td align="char" rowspan="1" colspan="1">0.05</td>
                          <td align="char" rowspan="1" colspan="1">0.434</td>
                          <td align="char" rowspan="1" colspan="1">−9.04</td>
                          <td align="char" rowspan="1" colspan="1">−0.18</td>
                          <td align="char" rowspan="1" colspan="1">0.00</td>
                          <td align="char" rowspan="1" colspan="1">0.051</td>
                          <td align="char" rowspan="1" colspan="1">−0.13</td>
                          <td align="char" rowspan="1" colspan="1">−0.32</td>
                          <td align="char" rowspan="1" colspan="1">0.07</td>
                          <td align="char" rowspan="1" colspan="1">0.193</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">1X ACCS minus placebo</td>
                          <td align="char" rowspan="1" colspan="1">−0.06</td>
                          <td align="char" rowspan="1" colspan="1">−0.14</td>
                          <td align="char" rowspan="1" colspan="1">0.02</td>
                          <td align="char" rowspan="1" colspan="1">0.121</td>
                          <td align="char" rowspan="1" colspan="1">−8.68</td>
                          <td align="char" rowspan="1" colspan="1">−0.18</td>
                          <td align="char" rowspan="1" colspan="1">0.00</td>
                          <td align="char" rowspan="1" colspan="1">0.062</td>
                          <td align="char" rowspan="1" colspan="1">−0.05</td>
                          <td align="char" rowspan="1" colspan="1">−0.23</td>
                          <td align="char" rowspan="1" colspan="1">0.14</td>
                          <td align="char" rowspan="1" colspan="1">0.641</td>
                        </tr>
                        <tr>
                          <td colspan="13" align="left" rowspan="1">12 days</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">0.3X ST266 minus placebo</td>
                          <td align="char" rowspan="1" colspan="1">−0.04</td>
                          <td align="char" rowspan="1" colspan="1">−0.13</td>
                          <td align="char" rowspan="1" colspan="1">0.05</td>
                          <td align="char" rowspan="1" colspan="1">0.394</td>
                          <td align="char" rowspan="1" colspan="1">−6.24</td>
                          <td align="char" rowspan="1" colspan="1">−0.16</td>
                          <td align="char" rowspan="1" colspan="1">0.04</td>
                          <td align="char" rowspan="1" colspan="1">0.226</td>
                          <td align="char" rowspan="1" colspan="1">−0.12</td>
                          <td align="char" rowspan="1" colspan="1">−0.33</td>
                          <td align="char" rowspan="1" colspan="1">0.09</td>
                          <td align="char" rowspan="1" colspan="1">0.263</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">1X ACCS minus placebo</td>
                          <td align="char" rowspan="1" colspan="1">−0.03</td>
                          <td align="char" rowspan="1" colspan="1">−0.13</td>
                          <td align="char" rowspan="1" colspan="1">0.07</td>
                          <td align="char" rowspan="1" colspan="1">0.519</td>
                          <td align="char" rowspan="1" colspan="1">−5.24</td>
                          <td align="char" rowspan="1" colspan="1">−0.15</td>
                          <td align="char" rowspan="1" colspan="1">0.05</td>
                          <td align="char" rowspan="1" colspan="1">0.311</td>
                          <td align="char" rowspan="1" colspan="1">−0.02</td>
                          <td align="char" rowspan="1" colspan="1">−0.21</td>
                          <td align="char" rowspan="1" colspan="1">0.17</td>
                          <td align="char" rowspan="1" colspan="1">0.819</td>
                        </tr>
                        <tr>
                          <td colspan="13" align="left" rowspan="1">42 days</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">0.3X ACCS minus placebo</td>
                          <td align="char" rowspan="1" colspan="1">−0.03</td>
                          <td align="char" rowspan="1" colspan="1">−0.12</td>
                          <td align="char" rowspan="1" colspan="1">0.06</td>
                          <td align="char" rowspan="1" colspan="1">0.528</td>
                          <td align="char" rowspan="1" colspan="1">−4.81</td>
                          <td align="char" rowspan="1" colspan="1">−0.12</td>
                          <td align="char" rowspan="1" colspan="1">0.03</td>
                          <td align="char" rowspan="1" colspan="1">0.219</td>
                          <td align="char" rowspan="1" colspan="1">0.11</td>
                          <td align="char" rowspan="1" colspan="1">−0.13</td>
                          <td align="char" rowspan="1" colspan="1">0.35</td>
                          <td align="char" rowspan="1" colspan="1">0.383</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">1X ACCS minus placebo</td>
                          <td align="char" rowspan="1" colspan="1">−0.10</td>
                          <td align="char" rowspan="1" colspan="1">−0.20</td>
                          <td align="char" rowspan="1" colspan="1">0.00</td>
                          <td align="char" rowspan="1" colspan="1">0.044<xref rid="jper10747-tbl1-note-0001" ref-type="table-fn">*</xref>
</td>
                          <td align="char" rowspan="1" colspan="1">−3.37</td>
                          <td align="char" rowspan="1" colspan="1">−0.11</td>
                          <td align="char" rowspan="1" colspan="1">0.04</td>
                          <td align="char" rowspan="1" colspan="1">0.392</td>
                          <td align="char" rowspan="1" colspan="1">−0.04</td>
                          <td align="char" rowspan="1" colspan="1">−0.29</td>
                          <td align="char" rowspan="1" colspan="1">0.21</td>
                          <td align="char" rowspan="1" colspan="1">0.760</td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <fn id="jper10747-tbl1-note-0001">
                        <label>*</label>
                        <p>Significant difference <italic toggle="yes">P</italic> &lt;0.05. Mean clinical differences, 95% confidence intervals (CI), and <italic toggle="yes">P</italic> values (not multiple‐comparison corrected) comparing 0.3X ST266 and 1X ST266 to placebo using GEE analysis (adjusted for baseline).</p>
                      </fn>
                    </table-wrap-foot>
                    <permissions>
                      <copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder>
                    </permissions>
                  </table-wrap>
                  <fig position="float" fig-type="FIGURE" id="jper10747-fig-0001">
                    <label>FIGURE 1</label>
                    <caption>
                      <p>Change in primary outcome, gingival index, at day 42. Differences were detected in gingival index (MGI) between placebo and both doses of ST266 at all time points; day 8, 12, and 42 (analysis adjusted for baseline differences). Statistically significant differences were noted for primary efficacy end point MGI at day 42 with 1X ST266 compared with placebo. *Significant difference at <italic toggle="yes">P</italic> &lt;0.05</p>
                    </caption>
                    <graphic xlink:href="JPER-92-1317-g002" position="anchor" id="jats-graphic-1"/>
                  </fig>
                  <fig position="float" fig-type="FIGURE" id="jper10747-fig-0002">
                    <label>FIGURE 2</label>
                    <caption>
                      <p>Change in bacterial counts of periodontal species. Fourteen periodontal bacteria were semi‐quantitively analyzed using DNA‐DNA hybridization checkerboard assay at baseline and at day 10 after treatments. Mean differences of change from baseline in ST266‐treated groups were compared with the change from baseline in place group. Both red and orange complex species known to be strongly associated with periodontal disease showed significant reductions on day 10 after treatment with ST266. Mean differences, 95% confidence intervals, and <italic toggle="yes">P</italic> values comparing 0.3X ST266 and 1X ST266 to placebo using GEE analysis. *Significant difference at <italic toggle="yes">P</italic> &lt;0.05</p>
                    </caption>
                    <graphic xlink:href="JPER-92-1317-g001" position="anchor" id="jats-graphic-3"/>
                  </fig>
                  <table-wrap position="float" id="jper10747-tbl-0002" content-type="TABLE">
                    <label>TABLE 2</label>
                    <caption>
                      <p>Odds of bleeding compared with placebo</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <col align="left" span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1"/>
                          <th style="border-bottom:solid 1px #000000" align="left" colspan="4" rowspan="1">Bleeding on probing (yes/no each site)</th>
                        </tr>
                        <tr>
                          <th align="left" rowspan="1" colspan="1"/>
                          <th align="char" rowspan="1" colspan="1"/>
                          <th style="border-bottom:solid 1px #000000" align="left" colspan="2" rowspan="1">95% CI</th>
                          <th align="char" rowspan="1" colspan="1"/>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" rowspan="1" colspan="1">Time point and comparison</th>
                          <th align="left" rowspan="1" colspan="1">Mean difference</th>
                          <th align="left" rowspan="1" colspan="1">Lower</th>
                          <th align="left" rowspan="1" colspan="1">Upper</th>
                          <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td colspan="5" align="left" rowspan="1">8 days</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" rowspan="1" colspan="1">0.3X ACCS minus placebo</td>
                          <td align="char" rowspan="1" colspan="1">−0.35</td>
                          <td align="char" rowspan="1" colspan="1">−0.88</td>
                          <td align="char" rowspan="1" colspan="1">0.18</td>
                          <td align="char" rowspan="1" colspan="1">0.197</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" rowspan="1" colspan="1">1X ACCS minus placebo</td>
                          <td align="char" rowspan="1" colspan="1">−0.75</td>
                          <td align="char" rowspan="1" colspan="1">−1.25</td>
                          <td align="char" rowspan="1" colspan="1">−0.24</td>
                          <td align="char" rowspan="1" colspan="1">0.004<xref rid="jper10747-tbl2-note-0001" ref-type="table-fn">*</xref>
</td>
                        </tr>
                        <tr>
                          <td colspan="5" align="left" rowspan="1">12 days</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" rowspan="1" colspan="1">0.3X ACCS minus placebo</td>
                          <td align="char" rowspan="1" colspan="1">−0.25</td>
                          <td align="char" rowspan="1" colspan="1">−0.89</td>
                          <td align="char" rowspan="1" colspan="1">0.40</td>
                          <td align="char" rowspan="1" colspan="1">0.452</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" rowspan="1" colspan="1">1X ACCS minus placebo</td>
                          <td align="char" rowspan="1" colspan="1">−0.73</td>
                          <td align="char" rowspan="1" colspan="1">−1.38</td>
                          <td align="char" rowspan="1" colspan="1">−0.07</td>
                          <td align="char" rowspan="1" colspan="1">0.030<xref rid="jper10747-tbl2-note-0001" ref-type="table-fn">*</xref>
</td>
                        </tr>
                        <tr>
                          <td colspan="5" align="left" rowspan="1">42 days</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" rowspan="1" colspan="1">0.3X ACCS minus placebo</td>
                          <td align="char" rowspan="1" colspan="1">−0.22</td>
                          <td align="char" rowspan="1" colspan="1">−0.70</td>
                          <td align="char" rowspan="1" colspan="1">0.25</td>
                          <td align="char" rowspan="1" colspan="1">0.355</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" rowspan="1" colspan="1">1X ACCS minus placebo</td>
                          <td align="char" rowspan="1" colspan="1">−0.40</td>
                          <td align="char" rowspan="1" colspan="1">−0.84</td>
                          <td align="char" rowspan="1" colspan="1">0.04</td>
                          <td align="char" rowspan="1" colspan="1">0.071</td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <fn id="jper10747-tbl2-note-0001">
                        <label>*</label>
                        <p>Significant <italic toggle="yes">P</italic> &lt;0.05; GEE/logistic model, repeated measures for each subject and outcome measured as 0/1 for no/yes.</p>
                      </fn>
                    </table-wrap-foot>
                    <permissions>
                      <copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder>
                    </permissions>
                  </table-wrap>
                  <p>Reductions in exploratory efficacy end points, PD and CAL, were detected at all time‐points with 0.3X ST266 and 1X ST266 at day 42 (PD, <italic toggle="yes">P</italic> = 0.005 and <italic toggle="yes">P</italic> = 0.008; and CAL, <italic toggle="yes">P</italic> = 0.002 and <italic toggle="yes">P</italic> = 0.001, respectively) compared with placebo (analysis adjusted for baseline differences) (Table <xref rid="jper10747-tbl-0003" ref-type="table">3</xref>). On day 12, there were changes for both PD (<italic toggle="yes">P</italic> = 0.03) and CAL (<italic toggle="yes">P</italic> = 0.014) in 1X ST266‐treated group compared with placebo. The changes from baseline were statistically significantly different when compared with placebo for both PD and CAL.</p>
                  <table-wrap position="float" id="jper10747-tbl-0003" content-type="TABLE">
                    <label>TABLE 3</label>
                    <caption>
                      <p>Exploratory clinical outcomes: probing depth and clinical attachment level</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <col align="left" span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1"/>
                          <th style="border-bottom:solid 1px #000000" align="left" colspan="4" rowspan="1">Probing depth</th>
                          <th style="border-bottom:solid 1px #000000" align="left" colspan="4" rowspan="1">Clinical attachment level</th>
                        </tr>
                        <tr>
                          <th align="left" rowspan="1" colspan="1"/>
                          <th align="char" rowspan="1" colspan="1"/>
                          <th style="border-bottom:solid 1px #000000" align="left" colspan="2" rowspan="1">95% CI</th>
                          <th align="char" rowspan="1" colspan="1"/>
                          <th align="char" rowspan="1" colspan="1"/>
                          <th style="border-bottom:solid 1px #000000" align="left" colspan="2" rowspan="1">95% CI</th>
                          <th align="char" rowspan="1" colspan="1"/>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" rowspan="1" colspan="1">Time point and comparison</th>
                          <th align="left" rowspan="1" colspan="1">Mean difference</th>
                          <th align="left" rowspan="1" colspan="1">Lower</th>
                          <th align="left" rowspan="1" colspan="1">Upper</th>
                          <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th>
                          <th align="left" rowspan="1" colspan="1">Mean difference</th>
                          <th align="left" rowspan="1" colspan="1">Lower</th>
                          <th align="left" rowspan="1" colspan="1">Upper</th>
                          <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td colspan="9" align="left" rowspan="1">8 days</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" rowspan="1" colspan="1">0.3X ACCS minus placebo</td>
                          <td align="char" rowspan="1" colspan="1">−0.041</td>
                          <td align="char" rowspan="1" colspan="1">−0.132</td>
                          <td align="char" rowspan="1" colspan="1">0.050</td>
                          <td align="char" rowspan="1" colspan="1">0.374</td>
                          <td align="char" rowspan="1" colspan="1">−0.050</td>
                          <td align="char" rowspan="1" colspan="1">−0.156</td>
                          <td align="char" rowspan="1" colspan="1">0.056</td>
                          <td align="char" rowspan="1" colspan="1">0.353</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" rowspan="1" colspan="1">1X ACCS minus placebo</td>
                          <td align="char" rowspan="1" colspan="1">−0.027</td>
                          <td align="char" rowspan="1" colspan="1">−0.116</td>
                          <td align="char" rowspan="1" colspan="1">0.062</td>
                          <td align="char" rowspan="1" colspan="1">0.556</td>
                          <td align="char" rowspan="1" colspan="1">−0.075</td>
                          <td align="char" rowspan="1" colspan="1">−0.174</td>
                          <td align="char" rowspan="1" colspan="1">0.024</td>
                          <td align="char" rowspan="1" colspan="1">0.137</td>
                        </tr>
                        <tr>
                          <td colspan="9" align="left" rowspan="1">12 days</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" rowspan="1" colspan="1">0.3X ACCS minus placebo</td>
                          <td align="char" rowspan="1" colspan="1">−0.103</td>
                          <td align="char" rowspan="1" colspan="1">−0.220</td>
                          <td align="char" rowspan="1" colspan="1">0.015</td>
                          <td align="char" rowspan="1" colspan="1">0.087</td>
                          <td align="char" rowspan="1" colspan="1">−0.072</td>
                          <td align="char" rowspan="1" colspan="1">−0.185</td>
                          <td align="char" rowspan="1" colspan="1">0.042</td>
                          <td align="char" rowspan="1" colspan="1">0.217</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" rowspan="1" colspan="1">1X ACCS minus placebo</td>
                          <td align="char" rowspan="1" colspan="1">−0.129</td>
                          <td align="char" rowspan="1" colspan="1">−0.245</td>
                          <td align="char" rowspan="1" colspan="1">−0.013</td>
                          <td align="char" rowspan="1" colspan="1">0.030<xref rid="jper10747-tbl3-note-0001" ref-type="table-fn">*</xref>
</td>
                          <td align="char" rowspan="1" colspan="1">−0.136</td>
                          <td align="char" rowspan="1" colspan="1">−0.244</td>
                          <td align="char" rowspan="1" colspan="1">−0.027</td>
                          <td align="char" rowspan="1" colspan="1">0.014<xref rid="jper10747-tbl3-note-0001" ref-type="table-fn">*</xref>
</td>
                        </tr>
                        <tr>
                          <td colspan="9" align="left" rowspan="1">42 days</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" rowspan="1" colspan="1">0.3X ACCS minus placebo</td>
                          <td align="char" rowspan="1" colspan="1">−0.134</td>
                          <td align="char" rowspan="1" colspan="1">−0.228</td>
                          <td align="char" rowspan="1" colspan="1">−0.040</td>
                          <td align="char" rowspan="1" colspan="1">0.005<xref rid="jper10747-tbl3-note-0001" ref-type="table-fn">*</xref>
</td>
                          <td align="char" rowspan="1" colspan="1">−0.173</td>
                          <td align="char" rowspan="1" colspan="1">−0.285</td>
                          <td align="char" rowspan="1" colspan="1">−0.062</td>
                          <td align="char" rowspan="1" colspan="1">0.002*</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" rowspan="1" colspan="1">1X ACCS minus placebo</td>
                          <td align="char" rowspan="1" colspan="1">−0.134</td>
                          <td align="char" rowspan="1" colspan="1">−0.234</td>
                          <td align="char" rowspan="1" colspan="1">−0.035</td>
                          <td align="char" rowspan="1" colspan="1">0.008<xref rid="jper10747-tbl3-note-0001" ref-type="table-fn">*</xref>
</td>
                          <td align="char" rowspan="1" colspan="1">−0.199</td>
                          <td align="char" rowspan="1" colspan="1">−0.314</td>
                          <td align="char" rowspan="1" colspan="1">−0.084</td>
                          <td align="char" rowspan="1" colspan="1">0.001*</td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <fn id="jper10747-tbl3-note-0001">
                        <label>*</label>
                        <p>Significant difference <italic toggle="yes">P</italic> &lt;0.05; mean clinical differences, 95% confidence intervals (CI), and <italic toggle="yes">P</italic> values (not multiple‐comparison corrected) comparing 0.3X ST266 and 1X ST266 to placebo using GEE analysis (adjusted for baseline).</p>
                      </fn>
                    </table-wrap-foot>
                    <permissions>
                      <copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder>
                    </permissions>
                  </table-wrap>
                  <p>The average daily change in PD, CAL, and MGI was calculated over time as rate of change. Placebo group showed increases in PD and CAL while both treatment groups (1X and 0.3XST266) had decreases in both PD and CAL over time (p<sub>0.3X </sub>= 0.07, p<sub>1X</sub> = 0.032) and CAL (<italic toggle="yes">P</italic> &lt;0.0001 for both groups compared with placebo). In addition, 1X ST266 showed significantly greater average change in MGI compared with placebo (<italic toggle="yes">P</italic> = 0.044) (see Table <xref rid="jper10747-supitem-0008" ref-type="supplementary-material">S6</xref> in online <italic toggle="yes">Journal of Periodontology</italic>).</p>
                  <p>Finally, the change in PD was also analyzed by stratifying the data according to PD. Both ST266 treatment groups showed statistically significant reductions at day 42 in shallow pockets (1 to 3 mm) and deeper pockets (4 to 9 mm) compared with placebo group (p<sub>0.3X </sub>= 0.022, p<sub>1X</sub> = 0.037 and p<sub>0.3X </sub>= 0.000, p<sub>1X</sub> = 0.003, respectively; data not shown).</p>
                  <p>The overall clinical periodontal measurement data by treatment group and by time point including baseline levels can be found in Table <xref rid="jper10747-supitem-0009" ref-type="supplementary-material">S7</xref> in online <italic toggle="yes">Journal of Periodontology</italic>.</p>
                </sec>
                <sec id="jper10747-sec-0280">
                  <label>3.3.2</label>
                  <title>Local and systemic inflammatory mediators</title>
                  <p>Treatment with both doses of ST266 resulted in significant reduction in GCF levels of IL‐1β and IL‐6 compared with placebo at day 12 after the tenth treatment (IL‐1β, <italic toggle="yes">P</italic> = 0.02, <italic toggle="yes">P</italic> = 0.015; and IL‐6, <italic toggle="yes">P</italic> = 0.005, <italic toggle="yes">P</italic> = 0.002, respectively) (Fig. <xref rid="jper10747-fig-0003" ref-type="fig">3</xref>). Only small differences were observed in the GCF levels of TNF‐α and IFN‐γ was undetectable in plasma and at very low or undetectable levels in the GCF.</p>
                  <fig position="float" fig-type="FIGURE" id="jper10747-fig-0003">
                    <label>FIGURE 3</label>
                    <caption>
                      <p>Change in levels of proinflammatory cytokines in gingival crevicular fluid. Levels of proinflammatory cytokines including IL‐1β, IL‐6, and TNF‐α in GCF were determined using a multiplexing platform. Mean differences of change from baseline in ST266‐treated groups were compared with the change from baseline in place group. Significant reductions were found in the levels of IL‐1β and IL‐6 in the GCF of subjects assigned to both 0.3X ST266 and 1X ST266 compared with placebo at day 12 after the tenth treatment (IL‐1β, <italic toggle="yes">P</italic> = 0.02, <italic toggle="yes">P</italic> = 0.015; and IL‐6, <italic toggle="yes">P</italic> = 0.005, <italic toggle="yes">P</italic> = 0.002, respectively). Mean differences, 95% confidence intervals, and <italic toggle="yes">P</italic> values comparing 0.3X ST266 and 1X ST266 to placebo using GEE analysis. *Significant difference at <italic toggle="yes">P</italic> &lt;0.05</p>
                    </caption>
                    <graphic xlink:href="JPER-92-1317-g003" position="anchor" id="jats-graphic-5"/>
                  </fig>
                  <p>Plasma levels of IL‐6 was significantly reduced compared with placebo in both 0.3 X ST266 and 1X ST266 groups 1 hour after the first treatment (<italic toggle="yes">P</italic> = 0.019 and <italic toggle="yes">P</italic> = 0.03, respectively) (see Table <xref rid="jper10747-supitem-0010" ref-type="supplementary-material">S8</xref> in online <italic toggle="yes">Journal of Periodontology</italic>).</p>
                </sec>
              </sec>
            </sec>
            <sec id="jper10747-sec-0290">
              <label>4</label>
              <title>DISCUSSION</title>
              <p>This was a “first in human” oral topical application of ST266 primarily for safety and preliminary efficacy on gingival inflammation. Subjects with gingivitis and/or periodontitis exhibiting at least 40% of BOP and 2.0 MGI score on average were included in the study. The safety analyses including reported adverse events, oral and hard tissue findings, vital signs, and routine laboratory tests (hematology, blood chemistry, C‐reactive protein, and urinalysis) showed no adverse outcomes related to study product. Reported adverse events by subjects in the ST266 groups were either unlikely related or not related. Minor differences were detected in some of the vital sign measures by treatment group at baseline; however, there was no evidence that over the course of treatment the temporal trends in vital signs were different by treatment group. Oral microbial analysis was conducted primarily for safety, which showed no adverse shift towards pathogenic microflora; on the contrary, both ST266 groups showed reduced levels of key red complex bacteria (<italic toggle="yes">Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola</italic>) reported to be highly associated with periodontal disease.<xref rid="jper10747-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="jper10747-bib-0030" ref-type="bibr"><sup>30</sup></xref>
</p>
              <p>As one of the main goals of periodontal treatment is reducing the inflammation, several anti‐inflammatory agents have been considered for use as adjunctive treatments including corticosteroids, disease modifying anti‐rheumatic drugs and non‐steroidal anti‐inflammatory drugs.<xref rid="jper10747-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="jper10747-bib-0031" ref-type="bibr"><sup>31</sup></xref> The studies evaluating the possible effects of corticosteroids and disease modifying anti‐rheumatic drugs on periodontal and gingival inflammation have been performed among the patients who were taking these drugs for other indications. Both drugs were associated with a range of side effects and did not have significant effects on reducing the inflammation in gingival tissues.<xref rid="jper10747-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="jper10747-bib-0031" ref-type="bibr"><sup>31</sup></xref>
</p>
              <p>On the other hand, non‐steroidal anti‐inflammatory drugs have been shown to reduce periodontal disease progression, especially in long‐term uses.<xref rid="jper10747-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="jper10747-bib-0032" ref-type="bibr"><sup>32</sup></xref> The most common finding of the studies was reduced alveolar bone loss when compared with the patients who were not taking non‐steroidal anti‐inflammatory drugs. Patients who took non‐steroidal anti‐inflammatory drugs for prolonged periods also tend to have reduced gingival inflammation and reduced PDs.<xref rid="jper10747-bib-0033" ref-type="bibr"><sup>33</sup></xref>, <xref rid="jper10747-bib-0034" ref-type="bibr"><sup>34</sup></xref>, <xref rid="jper10747-bib-0035" ref-type="bibr"><sup>35</sup></xref> However, a high rate of side effects were also associated with long‐term use of non‐steroidal anti‐inflammatory drugs including gastrointestinal, renal and hemostatic side effects, hypersensitivity reactions, headaches, dizziness, and vertigo.<xref rid="jper10747-bib-0007" ref-type="bibr"><sup>7</sup></xref> In our study, significantly reduced gingival and local inflammation as well as PD were observed with no adverse events related to any of the doses of ST266.</p>
              <p>Recently, several studies have reported the potential use of probiotics for reducing gingival inflammation.<xref rid="jper10747-bib-0036" ref-type="bibr"><sup>36</sup></xref>, <xref rid="jper10747-bib-0037" ref-type="bibr"><sup>37</sup></xref>, <xref rid="jper10747-bib-0038" ref-type="bibr"><sup>38</sup></xref> Although some individual studies lean towards the use of probiotics, in a meta‐analysis in 2020 it was concluded that there is weak evidence to support the use of probiotics in gingivitis.<xref rid="jper10747-bib-0036" ref-type="bibr"><sup>36</sup></xref> Here, we demonstrate improvement in most of the clinical parameters tested with the use of ST266 over 42 days. The primary preliminary endpoint, modified gingival index, was reduced at day 42 by 1X ST266 compared with placebo. Both 0.3X ST266 and 1X ST266 resulted in reductions in PD and clinical attachment loss at day 42 with an overall trend in reduction throughout the course of the treatment despite any mechanical treatment. The PD and CAL reductions were noticeable as early as day 12 with 1X ST266 group compared with placebo. Although, the study primarily tested the novel treatments on gingival inflammation in patients with gingivitis and therefore powered for detecting significant differences in gingival inflammation, the study protocol also included patients with periodontal disease exhibiting similar level of gingival inflammation. Reductions in both PD and attachment loss offer a promising benefit from ST266 for the treatment of periodontal diseases.</p>
              <p>A combination of antibacterial and anti‐inflammatory agents is considered as a viable option for the treatment of periodontal diseases.<xref rid="jper10747-bib-0009" ref-type="bibr"><sup>9</sup></xref> For example, adjunctive use of systemic tetracycline and ibuprofen with scaling and root planing was shown to be beneficial when compared with scaling and root planing only.<xref rid="jper10747-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="jper10747-bib-0039" ref-type="bibr"><sup>39</sup></xref> A macrolide antibiotic, azithromycin, which has both antibacterial and anti‐inflammatory properties,<xref rid="jper10747-bib-0040" ref-type="bibr"><sup>40</sup></xref> was also reported to improve the efficacy of non‐surgical periodontal therapy by reducing the PD, BOP, and increasing the gain of attachment.<xref rid="jper10747-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="jper10747-bib-0041" ref-type="bibr"><sup>41</sup></xref> The results of the studies using antibiotics as adjunctive periodontal therapies seems to have promising outcomes with regard to the clinical outcomes, however potential changes in the host microbiome, a small risk of adverse cardiovascular events and the risk of antibiotic resistance should be considered as a downside of these treatment alternatives.<xref rid="jper10747-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="jper10747-bib-0042" ref-type="bibr"><sup>42</sup></xref>
</p>
              <p>In the present study, parallel to reductions in gingival index and PD, inflammatory cytokines in the gingival crevicular fluid, IL‐1β, and IL‐6, were reduced at day 12 in response to both ST266 treatments. Concurrently, levels of subgingival periodontal microorganisms <italic toggle="yes">F. nucleatum, T. denticola</italic>, and <italic toggle="yes">T. forsythia</italic> showed reductions compared with placebo at day 12 in both the 0.3X or 1X ST266 groups suggesting that ST266 treatment can modulate the inflammatory response and subgingival microbiome shifting the balance from disease associated to health associated profiles. Studies designed to determine the impact of ST266 treatment on oral microbiome are warranted to further prove this hypothesis.</p>
              <p>A relatively new approach is the administration of omega 3 polyunsaturated fatty acids (ω‐3 PUFA) and acetylsalisylic acid (ASA) as adjuncts to periodontal debridement for the treatment of periodontitis to control inflammation.<xref rid="jper10747-bib-0043" ref-type="bibr"><sup>43</sup></xref>, <xref rid="jper10747-bib-0044" ref-type="bibr"><sup>44</sup></xref> In a study comparing the use of ω‐3 PUFA and ASA for two different treatment protocols in patients with diabetes, reductions in IL‐1β and IL‐6 were reported, especially in patients who had periodontal debridement before ω‐3 PUFA and ASA administration.<xref rid="jper10747-bib-0045" ref-type="bibr"><sup>45</sup></xref> Similar to ω‐3 PUFA and ASA, in our study ST266 reduced IL‐1β and IL‐6 levels by day 10 (in 12 days) and could be considered a novel therapeutic in patients with periodontal disease complicated by systemic inflammatory diseases including diabetes. The decreased levels of decorin, an inflammatory biomarker,<xref rid="jper10747-bib-0046" ref-type="bibr"><sup>46</sup></xref>, <xref rid="jper10747-bib-0047" ref-type="bibr"><sup>47</sup></xref> in plasma also indicates the anti‐inflammatory actions of topical oral ST266 that warrants further investigation on the benefits of ST266 on systemic inflammation through oral tissues. The results of this Phase 1 clinical proof‐of‐principal study support the hypothesis that topical application of ST266 reduces periodontal inflammation at both clinical and biochemical levels in a short period (2 weeks) with stability at 6 weeks post‐treatment. Reduced numbers of periodontal pathogens in ST266‐treated sites also support the concept of host‐modulation as an optimal therapeutic approach for this multifactorial disease.</p>
              <p>As a Phase 1 proof‐of‐principle clinical trial primarily focusing on the safety, the study had small sample size and therefore limited power for detecting differences in clinical efficacy outcome measures. However, the study results, for the first time, demonstrated that ST266 could be a potentially impactful therapeutic for the treatment of periodontal disease with consistent improvements on the clinical (gingival inflammation) and biological end points (local cytokines and microbial species). Although there were close‐to‐significant reductions, this study likely underestimated the true impact on systemic proinflammatory cytokines and larger trials will be necessary to test the potential of ST266 as a topical treatment on the regulation of systemic inflammatory mediators. The relatively short duration of the treatment (10 consecutive days) should also be tested for long‐term effects especially due to the chronic and progressive nature of periodontal disease. Further, plaque sampling from four posterior sites may not be representative of periodontally affected sites and the checkerboard analysis technique only examined a subset of the gingival microbiome. Yet, significant reductions have been shown with periodontal pathogens including <italic toggle="yes">P. gingivalis</italic> and <italic toggle="yes">T. forsythia</italic>.</p>
            </sec>
            <sec id="jper10747-sec-0300">
              <label>5</label>
              <title>CONCLUSIONS</title>
              <p>Topical ST266 applied directly on to marginal gingiva was safe and effective in reducing gingival inflammation in 6 weeks. With statistically significant reductions in BOP, PD, and CAL, ST266 shows promising therapeutic value as a novel host modulatory compound in the treatment of periodontal diseases. Longitudinal studies with large sample sizes and dose response designs are warranted to characterize its clinical efficacy and potential impact on inflammatory conditions related to periodontal diseases.</p>
            </sec>
            <sec sec-type="COI-statement" id="jper10747-sec-0320">
              <p>All authors except Drs. Steed and Van Dyke report no conflicts of interest related to this study. Dr. Steed is the Executive VP of Medical Affairs at Noveome Biotherapeutics, owns stocks, and filed multiple patents on ST266. Dr. Van Dyke has been a paid advisor and owns stocks in Noveome Biotherapeutics.</p>
            </sec>
            <sec id="jper10747-sec-0330">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p>Hatice Hasturk substantially contributed to conception and design, acquisition, analysis, and interpretation of data; drafted and critically revised the article for important intellectual content. David Steed contributed to conception and design, analysis and interpretation of the data, critically revised the article. Emre Tosun and Thomas E. Van Dyke critically revised the manuscript with important intellectual contribution. Melissa Martins and Constantinos Floros performed data and sample collection and data entry. Maryann Cugini supervised randomization, study execution and data acquisition. Daniel Nguyen and Danielle Stephens performed analysis of biological specimens and critically revised the analytical sections. Jacqueline Starr performed statistical analyses and contributed to interpretation of the results. All authors approved the final version of the article and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.</p>
            </sec>
            <sec id="jper10747-sec-0340">
              <p>Technical and financial support was provided by a grant from Noveome Biotherapeutics. The study product, ST266, was provided by Noveome Biotherapeutics.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="jper10747-supitem-0001" position="float" content-type="local-data">
                <caption>
                  <p>Figure S1. Participant recruitment and completion status.</p>
                </caption>
                <media xlink:href="JPER-92-1317-s006.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="jper10747-supitem-0002" position="float" content-type="local-data">
                <caption>
                  <p>Figure S2. Subgingival plaque microbial analysis.</p>
                </caption>
                <media xlink:href="JPER-92-1317-s004.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="jper10747-supitem-0003" position="float" content-type="local-data">
                <caption>
                  <p>Table S1. Study design and treatment period.</p>
                </caption>
                <media xlink:href="JPER-92-1317-s007.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="jper10747-supitem-0004" position="float" content-type="local-data">
                <caption>
                  <p>Table S2. Demographics, periodontal and study completion status by treatment group.</p>
                </caption>
                <media xlink:href="JPER-92-1317-s003.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="jper10747-supitem-0005" position="float" content-type="local-data">
                <caption>
                  <p>Table S3. Adverse events by body system.</p>
                </caption>
                <media xlink:href="JPER-92-1317-s001.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="jper10747-supitem-0006" position="float" content-type="local-data">
                <caption>
                  <p>Table S4. Vital signs by time by group.</p>
                </caption>
                <media xlink:href="JPER-92-1317-s002.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="jper10747-supitem-0007" position="float" content-type="local-data">
                <caption>
                  <p>Table S5. Microbial analysis.</p>
                </caption>
                <media xlink:href="JPER-92-1317-s009.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="jper10747-supitem-0008" position="float" content-type="local-data">
                <caption>
                  <p>Table S6. Rate of change in PD and CAL.</p>
                </caption>
                <media xlink:href="JPER-92-1317-s008.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="jper10747-supitem-0009" position="float" content-type="local-data">
                <caption>
                  <p>Table S7. Mean clinical periodontal measurements by group and time point.</p>
                </caption>
                <media xlink:href="JPER-92-1317-s005.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="jper10747-supitem-0010" position="float" content-type="local-data">
                <caption>
                  <p>Table S8. Levels of proinflammatory cytokines in plasma.</p>
                </caption>
                <media xlink:href="JPER-92-1317-s010.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="jper10747-sec-0310">
              <title>ACKNOWLEDGMENTS</title>
              <p>The authors would like to thank the Forsyth Institute Center for Clinical and Translational Research staff Christine Roberts, Homa Sherzai, Gay Torresyap, Elida Salazar, Marie Letteri, Molly Dunne, Nicole Tejeda, and Hernide Deribert for their efforts in subject recruitment retention and data collection. The statistical support by Ping Shi for safety analyses is greatly appreciated. The authors also acknowledge the technical and financial support by the sponsor, Noveome Biotherapeutics.</p>
            </ack>
            <fn-group>
              <fn id="jper10747-note-0001">
                <label>*</label>
                <p>Meso Scale Discovery, Rockville, MD</p>
              </fn>
              <fn id="jper10747-note-0002">
                <label>†</label>
                <p>Meso Scale Discovery Model 1200 Sector Imager 2400, San Diego, CA</p>
              </fn>
              <fn id="jper10747-note-0003">
                <label>‡</label>
                <p>Hu‐Friedy, Chicago IL</p>
              </fn>
              <fn id="jper10747-note-0004">
                <label>§</label>
                <p>Oraflow, Smithtown, NY</p>
              </fn>
              <fn id="jper10747-note-0005">
                <label>¶</label>
                <p>Luminex Human High Sensitivity Cytokine Magnetic Panel B, R&amp;D Systems, Minneapolis, MN</p>
              </fn>
              <fn id="jper10747-note-0006">
                <label>#</label>
                <p>Luminex 100 Bio‐Plex Platform, Bio‐Rad Laboratories, Hercules, CA</p>
              </fn>
              <fn id="jper10747-note-0007">
                <label>**</label>
                <p>Bio‐Plex Manager version 6.1, Bio‐Rad Laboratories, Hercules, CA</p>
              </fn>
              <fn id="jper10747-note-0008">
                <label>††</label>
                <p>Afton Scientific, Charlottesville, VA</p>
              </fn>
              <fn id="jper10747-note-0009">
                <label>‡‡</label>
                <p>Noveome Biotherapeutics, Pittsburgh, PA</p>
              </fn>
              <fn id="jper10747-note-0010">
                <label>§§</label>
                <p>Stata version 13.0; College Station, TX</p>
              </fn>
            </fn-group>
            <ref-list id="jper10747-bibl-0001">
              <title>REFERENCES</title>
              <ref id="jper10747-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0001"><string-name><surname>Eke</surname><given-names>PI</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name><surname>Lu</surname><given-names>H</given-names></string-name>, et al. <article-title>Predicting periodontitis at state and local levels in the United States</article-title>. <source>J Dent Res</source>. <year>2016</year>;<volume>95</volume>:<fpage>515</fpage>‐<lpage>522</lpage>.<pub-id pub-id-type="pmid">26848071</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0002"><string-name><surname>Hajishengallis</surname><given-names>G</given-names></string-name>. <article-title>Periodontitis: from microbial immune subversion to systemic inflammation</article-title>. <source>Nat Rev Immunol</source>. <year>2015</year>;<volume>15</volume>:<fpage>30</fpage>‐<lpage>44</lpage>.<pub-id pub-id-type="pmid">25534621</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0003"><string-name><surname>Cekici</surname><given-names>A</given-names></string-name>, <string-name><surname>Kantarci</surname><given-names>A</given-names></string-name>, <string-name><surname>Hasturk</surname><given-names>H</given-names></string-name>, <string-name><surname>Van Dyke</surname><given-names>TE</given-names></string-name>. <article-title>Inflammatory and immune pathways in the pathogenesis of periodontal disease</article-title>. <source>Periodontol 2000</source>. <year>2014</year>;<volume>64</volume>:<fpage>57</fpage>‐<lpage>80</lpage>.<pub-id pub-id-type="pmid">24320956</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0004"><string-name><surname>Hajishengallis</surname><given-names>G</given-names></string-name>, <string-name><surname>Darveau</surname><given-names>RP</given-names></string-name>, <string-name><surname>Curtis</surname><given-names>MA</given-names></string-name>. <article-title>The keystone‐pathogen hypothesis</article-title>. <source>Nat Rev Microbiol</source>. <year>2012</year>;<volume>10</volume>:<fpage>717</fpage>‐<lpage>725</lpage>.<pub-id pub-id-type="pmid">22941505</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0005"><string-name><surname>Heitz‐Mayfield</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Lang</surname><given-names>NP</given-names></string-name>. <article-title>Surgical and nonsurgical periodontal therapy. Learned and unlearned concepts</article-title>. <source>Periodontol 2000</source>. <year>2013</year>;<volume>62</volume>:<fpage>218</fpage>‐<lpage>231</lpage>.<pub-id pub-id-type="pmid">23574468</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0006"><string-name><surname>Haffajee</surname><given-names>AD</given-names></string-name>, <string-name><surname>Socransky</surname><given-names>SS</given-names></string-name>. <article-title>Introduction to microbial aspects of periodontal biofilm communities, development and treatment</article-title>. <source>Periodontol 2000</source>. <year>2006</year>;<volume>42</volume>:<fpage>7</fpage>‐<lpage>12</lpage>.<pub-id pub-id-type="pmid">16930302</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0007"><string-name><surname>Preshaw</surname><given-names>PM</given-names></string-name>. <article-title>Host modulation therapy with anti‐inflammatory agents</article-title>. <source>Periodontol 2000</source>. <year>2018</year>;<volume>76</volume>:<fpage>131</fpage>‐<lpage>149</lpage>.<pub-id pub-id-type="pmid">29193331</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0008"><string-name><surname>Loffler</surname><given-names>C</given-names></string-name>, <string-name><surname>Bohmer</surname><given-names>F</given-names></string-name>. <article-title>The effect of interventions aiming to optimise the prescription of antibiotics in dental care‐A systematic review</article-title>. <source>Plos One</source>. <year>2017</year>;<volume>12</volume>:<elocation-id>e0188061</elocation-id>.<pub-id pub-id-type="pmid">29136646</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0009"><string-name><surname>Bartold</surname><given-names>PM</given-names></string-name>, <string-name><surname>Van Dyke</surname><given-names>TE</given-names></string-name>. <article-title>Host modulation: controlling the inflammation to control the infection</article-title>. <source>Periodontol 2000</source>. <year>2017</year>;<volume>75</volume>:<fpage>317</fpage>‐<lpage>329</lpage>.<pub-id pub-id-type="pmid">28758299</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0010"><string-name><surname>Steed</surname><given-names>DL</given-names></string-name>, <string-name><surname>Trumpower</surname><given-names>C</given-names></string-name>, <string-name><surname>Duffy</surname><given-names>D</given-names></string-name>, et al. <article-title>Amnion‐derived cellular cytokine solution: a physiological combination of cytokines for wound healing</article-title>. <source>Eplasty</source>. <year>2008</year>;<volume>8</volume>:<elocation-id>e18</elocation-id>.<pub-id pub-id-type="pmid">18461121</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0011"><string-name><surname>Kang</surname><given-names>NH</given-names></string-name>, <string-name><surname>Hwang</surname><given-names>KA</given-names></string-name>, <string-name><surname>Kim</surname><given-names>SU</given-names></string-name>, et al. <article-title>Potential antitumor therapeutic strategies of human amniotic membrane and amniotic fluid‐derived stem cells</article-title>. <source>Cancer Gene Ther</source>. <year>2012</year>;<volume>19</volume>:<fpage>517</fpage>‐<lpage>522</lpage>.<pub-id pub-id-type="pmid">22653384</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0012"><string-name><surname>Bergmann</surname><given-names>J</given-names></string-name>, <string-name><surname>Hackl</surname><given-names>F</given-names></string-name>, <string-name><surname>Koyama</surname><given-names>T</given-names></string-name>, et al. <article-title>The effect of amnion‐derived cellular cytokine solution on the epithelialization of partial‐thickness donor site wounds in normal and streptozotocin‐induced diabetic swine</article-title>. <source>Eplasty</source>. <year>2009</year>;<volume>9</volume>:<elocation-id>e49</elocation-id>.<pub-id pub-id-type="pmid">19936023</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0013"><string-name><surname>Franz</surname><given-names>MG</given-names></string-name>, <string-name><surname>Payne</surname><given-names>WG</given-names></string-name>, <string-name><surname>Xing</surname><given-names>L</given-names></string-name>, et al. <article-title>The use of amnion‐derived cellular cytokine solution to improve healing in acute and chronic wound models</article-title>. <source>Eplasty</source>. <year>2008</year>;<volume>8</volume>:<elocation-id>e21</elocation-id>.<pub-id pub-id-type="pmid">18470282</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0014"><string-name><surname>Uberti</surname><given-names>MG</given-names></string-name>, <string-name><surname>Ko</surname><given-names>F</given-names></string-name>, <string-name><surname>Pierpont</surname><given-names>YN</given-names></string-name>, et al. <article-title>The use of amnion‐derived cellular cytokine solution (ACCS) in accelerating closure of interstices in explanted meshed human skin grafts</article-title>. <source>Eplasty</source>. <year>2009</year>;<volume>9</volume>:<elocation-id>e12</elocation-id>.<pub-id pub-id-type="pmid">19396338</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0015"><string-name><surname>Uberti</surname><given-names>MG</given-names></string-name>, <string-name><surname>Pierpont</surname><given-names>YN</given-names></string-name>, <string-name><surname>Ko</surname><given-names>F</given-names></string-name>, et al. <article-title>Amnion‐derived cellular cytokine solution (ACCS) promotes migration of keratinocytes and fibroblasts</article-title>. <source>Ann Plast Surg</source>. <year>2010</year>;<volume>64</volume>:<fpage>632</fpage>‐<lpage>635</lpage>.<pub-id pub-id-type="pmid">20395817</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0016"><string-name><surname>Pierpont</surname><given-names>YN</given-names></string-name>, <string-name><surname>Uberti</surname><given-names>MG</given-names></string-name>, <string-name><surname>Ko</surname><given-names>F</given-names></string-name>, et al. <article-title>Individualized, targeted wound treatment based on the tissue bacterial level as a biological marker</article-title>. <source>Am J Surg</source>. <year>2011</year>;<volume>202</volume>:<fpage>220</fpage>‐<lpage>224</lpage>.<pub-id pub-id-type="pmid">21185550</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0017"><string-name><surname>Hasturk</surname><given-names>H</given-names></string-name>, <string-name><surname>Stephens</surname><given-names>L</given-names></string-name>, <string-name><surname>Andrada</surname><given-names>D</given-names></string-name>, <string-name><surname>Nguyen</surname><given-names>A</given-names></string-name>, <string-name><surname>Andrada</surname><given-names>C</given-names></string-name>, <string-name><surname>Van Dyke</surname><given-names>T</given-names></string-name>. <article-title>Preventive role of amnion‐derived cellular cytokine solution in periodontal inflammation</article-title>. <source>J Dent Res</source>. <year>2013</year>;<volume>92</volume>(<issue>Spec. Iss. B</issue>):<fpage>1604</fpage>.</mixed-citation>
              </ref>
              <ref id="jper10747-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0018"><string-name><surname>Hasturk</surname><given-names>H</given-names></string-name>, <string-name><surname>Andrada</surname><given-names>L</given-names></string-name>, <string-name><surname>Nguyen</surname><given-names>D</given-names></string-name>, et al. <article-title>Amnion‐derived cellular cytokine solution in the treatment of experimental periodontitis</article-title>. <source>J Dent Res</source>. <year>2013</year>;<volume>92</volume>(<issue>Spec. Iss. B</issue>):<fpage>1605</fpage>.</mixed-citation>
              </ref>
              <ref id="jper10747-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0019"><string-name><surname>Uberti</surname><given-names>MG</given-names></string-name>, <string-name><surname>Lufkin</surname><given-names>AE</given-names></string-name>, <string-name><surname>Pierpont</surname><given-names>YN</given-names></string-name>, et al. <article-title>Amnion‐derived cellular cytokine solution promotes macrophage activity</article-title>. <source>Ann Plast Surg</source>. <year>2011</year>;<volume>66</volume>:<fpage>575</fpage>‐<lpage>580</lpage>.<pub-id pub-id-type="pmid">21451377</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0020"><string-name><surname>Deng‐Bryant</surname><given-names>Ying</given-names></string-name>, <string-name><surname>Readnower</surname><given-names>Ryan D.</given-names></string-name>, <string-name><surname>Leung</surname><given-names>Lai Yee</given-names></string-name>, <string-name><surname>Cunningham</surname><given-names>Tracy L.</given-names></string-name>, <string-name><surname>Shear</surname><given-names>Deborah A.</given-names></string-name>, <string-name><surname>Tortella</surname><given-names>Frank C.</given-names></string-name><article-title>Treatment with amnion‐derived cellular cytokine solution (ACCS) induces persistent motor improvement and ameliorates neuroinflammation in a rat model of penetrating ballistic‐like brain injury</article-title>. <source>Restorative Neurology and Neuroscience</source>. <year>2015</year>;<volume>33</volume>(<issue>2</issue>):<fpage>189</fpage>–<lpage>203</lpage>. <pub-id pub-id-type="doi">10.3233/rnn-140455</pub-id>.<pub-id pub-id-type="pmid">25588460</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0021"><string-name><surname>Khan</surname><given-names>RS</given-names></string-name>, <string-name><surname>Dine</surname><given-names>K</given-names></string-name>, <string-name><surname>Wessel</surname><given-names>H</given-names></string-name>, <string-name><surname>Brown</surname><given-names>L</given-names></string-name>, <string-name><surname>Shindler</surname><given-names>KS</given-names></string-name>. <article-title>Effects of varying intranasal treatment regimens in ST266‐mediated retinal ganglion cell neuroprotection</article-title>. <italic toggle="yes">J Neuroophthalmol</italic>. <year>2019</year>;<volume>39</volume>:<fpage>191</fpage>‐<lpage>199</lpage>.</mixed-citation>
              </ref>
              <ref id="jper10747-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0022"><string-name><surname>Trombetta</surname><given-names>M</given-names></string-name>, <string-name><surname>Julian</surname><given-names>TB</given-names></string-name>, <string-name><surname>Wickerham</surname><given-names>DL</given-names></string-name>, <string-name><surname>Steed</surname><given-names>DL</given-names></string-name>. <article-title>Safety Profile of Amnion‐Derived Cellular Cytokine Solution (ACCS) following topical skin application in patients receiving breast radiotherapy</article-title>. <source>Eplasty</source>. <year>2015</year>;<volume>15</volume>:<elocation-id>e33</elocation-id>.<pub-id pub-id-type="pmid">26240671</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0023"><string-name><surname>Guan</surname><given-names>L</given-names></string-name>, <string-name><surname>Suggs</surname><given-names>A</given-names></string-name>, <string-name><surname>Galan</surname><given-names>E</given-names></string-name>, <string-name><surname>Lam</surname><given-names>M</given-names></string-name>, <string-name><surname>Baron</surname><given-names>ED</given-names></string-name>. <article-title>Topical application of ST266 reduces UV‐induced skin damage</article-title>. <source>Clin Cosmet Investig Dermatol</source>. <year>2017</year>;<volume>10</volume>:<fpage>459</fpage>‐<lpage>471</lpage>.</mixed-citation>
              </ref>
              <ref id="jper10747-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0024"><string-name><surname>Socransky</surname><given-names>SS</given-names></string-name>, <string-name><surname>Smith</surname><given-names>C</given-names></string-name>, <string-name><surname>Martin</surname><given-names>L</given-names></string-name>, <string-name><surname>Paster</surname><given-names>BJ</given-names></string-name>, <string-name><surname>Dewhirst</surname><given-names>FE</given-names></string-name>, <string-name><surname>Levin</surname><given-names>AE</given-names></string-name>. <article-title>Checkerboard” DNA‐DNA hybridization</article-title>. <source>Biotechniques</source>. <year>1994</year>;<volume>17</volume>:<fpage>788</fpage>‐<lpage>792</lpage>.<pub-id pub-id-type="pmid">7833043</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0025"><string-name><surname>Hasturk</surname><given-names>H</given-names></string-name>, <string-name><surname>Nunn</surname><given-names>M</given-names></string-name>, <string-name><surname>Warbington</surname><given-names>M</given-names></string-name>, <string-name><surname>Van Dyke</surname><given-names>TE</given-names></string-name>. <article-title>Efficacy of a fluoridated hydrogen peroxide‐based mouthrinse for the treatment of gingivitis: a randomized clinical trial</article-title>. <source>J Periodontol</source>. <year>2004</year>;<volume>75</volume>:<fpage>57</fpage>‐<lpage>65</lpage>.<pub-id pub-id-type="pmid">15025217</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0026"><string-name><surname>Lobene</surname><given-names>RR</given-names></string-name>, <string-name><surname>Weatherford</surname><given-names>T</given-names></string-name>, <string-name><surname>Ross</surname><given-names>NM</given-names></string-name>, <string-name><surname>Lamm</surname><given-names>RA</given-names></string-name>, <string-name><surname>Menaker</surname><given-names>L</given-names></string-name>. <article-title>A modified gingival index for use in clinical trials</article-title>. <source>Clin Prevent Dent</source>. <year>1986</year>;<volume>8</volume>:<fpage>3</fpage>‐<lpage>6</lpage>.</mixed-citation>
              </ref>
              <ref id="jper10747-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0027"><string-name><surname>Turesky</surname><given-names>S</given-names></string-name>, <string-name><surname>Gilmore</surname><given-names>ND</given-names></string-name>, <string-name><surname>Glickman</surname><given-names>I</given-names></string-name>. <article-title>Reduced plaque formation by the chloromethyl analogue of victamine C</article-title>. <source>J Periodontol</source>. <year>1970</year>;<volume>41</volume>:<fpage>41</fpage>‐<lpage>43</lpage>.<pub-id pub-id-type="pmid">5264376</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="book" id="jper10747-cit-0028"><string-name><surname>Hasturk</surname><given-names>H</given-names></string-name>, <string-name><surname>Cugini</surname><given-names>M</given-names></string-name>. <part-title>Examiner standardization and calibration for oral and periodontal regeneration studies</part-title>. In: <person-group person-group-type="editor"><string-name><surname>VG</surname><given-names>W</given-names></string-name></person-group>, <person-group person-group-type="editor"><string-name><surname>Lang</surname><given-names>NP</given-names></string-name></person-group>, <person-group person-group-type="editor"><string-name><surname>Tonetti</surname><given-names>MS</given-names></string-name></person-group>, eds. <source>Osteology Guidelines for Oral and Maxillofacial Regeneration Clinical Research</source>. <publisher-loc>Berlin, Germany</publisher-loc>: <publisher-name>Quintessence Publishing Co., Inc.</publisher-name>; <year>2014</year>:<fpage>9</fpage> .</mixed-citation>
              </ref>
              <ref id="jper10747-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0029"><string-name><surname>Browne</surname><given-names>RW</given-names></string-name>, <string-name><surname>Kantarci</surname><given-names>A</given-names></string-name>, <string-name><surname>LaMonte</surname><given-names>MJ</given-names></string-name>, et al. <article-title>Performance of multiplex cytokine assays in serum and saliva among community‐dwelling postmenopausal women</article-title>. <source>Plos One</source>. <year>2013</year>;<volume>8</volume>:<elocation-id>e59498</elocation-id>.<pub-id pub-id-type="pmid">23577067</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0030"><string-name><surname>Ramseier</surname><given-names>CA</given-names></string-name>, <string-name><surname>Kinney</surname><given-names>JS</given-names></string-name>, <string-name><surname>Herr</surname><given-names>AE</given-names></string-name>, et al. <article-title>Identification of pathogen and host‐response markers correlated with periodontal disease</article-title>. <source>J Periodontol</source>. <year>2009</year>;<volume>80</volume>:<fpage>436</fpage>‐<lpage>446</lpage>.<pub-id pub-id-type="pmid">19254128</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0031"><string-name><surname>Seymour</surname><given-names>RA</given-names></string-name>, <string-name><surname>Heasman</surname><given-names>PA</given-names></string-name>. <article-title>Drugs and the periodontium</article-title>. <source>J Clin Periodontol</source>. <year>1988</year>;<volume>15</volume>:<fpage>1</fpage>‐<lpage>16</lpage>.<pub-id pub-id-type="pmid">3276739</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0032"><string-name><surname>Waite</surname><given-names>IM</given-names></string-name>, <string-name><surname>Saxton</surname><given-names>CA</given-names></string-name>, <string-name><surname>Young</surname><given-names>A</given-names></string-name>, <string-name><surname>Wagg</surname><given-names>BJ</given-names></string-name>, <string-name><surname>Corbett</surname><given-names>M</given-names></string-name>. <article-title>The periodontal status of subjects receiving non‐steroidal anti‐inflammatory drugs</article-title>. <source>J Periodontal Res</source>. <year>1981</year>;<volume>16</volume>:<fpage>100</fpage>‐<lpage>108</lpage>.<pub-id pub-id-type="pmid">6453964</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0033"><string-name><surname>Feldman</surname><given-names>RS</given-names></string-name>, <string-name><surname>Szeto</surname><given-names>B</given-names></string-name>, <string-name><surname>Chauncey</surname><given-names>HH</given-names></string-name>, <string-name><surname>Goldhaber</surname><given-names>P</given-names></string-name>. <article-title>Non‐steroidal anti‐inflammatory drugs in the reduction of human alveolar bone loss</article-title>. <source>J Clin Periodontol</source>. <year>1983</year>;<volume>10</volume>:<fpage>131</fpage>‐<lpage>136</lpage>.<pub-id pub-id-type="pmid">6573339</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0034"><string-name><surname>Reiff</surname><given-names>RL</given-names></string-name>, <string-name><surname>White</surname><given-names>CL</given-names></string-name>, <string-name><surname>Overman</surname><given-names>P</given-names></string-name>, <string-name><surname>ElAttar</surname><given-names>T</given-names></string-name>, <string-name><surname>Platt</surname><given-names>RD</given-names></string-name>. <article-title>Aspirin, buffered aspirin, and effervescent buffer rinses in reducing gingival inflammation in patients with gingivitis and early periodontitis</article-title>. <source>Quintessence Int</source>. <year>1988</year>;<volume>19</volume>:<fpage>287</fpage>‐<lpage>290</lpage>.<pub-id pub-id-type="pmid">3269579</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0035"><string-name><surname>Vogel</surname><given-names>RI</given-names></string-name>, <string-name><surname>Copper</surname><given-names>SA</given-names></string-name>, <string-name><surname>Schneider</surname><given-names>LG</given-names></string-name>, <string-name><surname>Goteiner</surname><given-names>D</given-names></string-name>. <article-title>The effects of topical steroidal and systemic nonsteroidal anti‐inflammatory drugs on experimental gingivitis in man</article-title>. <source>J Periodontol</source>. <year>1984</year>;<volume>55</volume>:<fpage>247</fpage>‐<lpage>251</lpage>.<pub-id pub-id-type="pmid">6585544</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0036"><string-name><surname>Akram</surname><given-names>Z</given-names></string-name>, <string-name><surname>Shafqat</surname><given-names>SS</given-names></string-name>, <string-name><surname>Aati</surname><given-names>S</given-names></string-name>, <string-name><surname>Kujan</surname><given-names>O</given-names></string-name>, <string-name><surname>Fawzy</surname><given-names>A</given-names></string-name>. <article-title>Clinical efficacy of probiotics in the treatment of gingivitis: a systematic review and meta‐analysis</article-title>. <source>Aust Dent J</source>. <year>2020</year>;<volume>65</volume>:<fpage>12</fpage>‐<lpage>20</lpage>.<pub-id pub-id-type="pmid">31682012</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0037"><string-name><surname>Montero</surname><given-names>E</given-names></string-name>, <string-name><surname>Iniesta</surname><given-names>M</given-names></string-name>, <string-name><surname>Rodrigo</surname><given-names>M</given-names></string-name>, et al. <article-title>Clinical and microbiological effects of the adjunctive use of probiotics in the treatment of gingivitis: a randomized controlled clinical trial</article-title>. <source>J Clin Periodontol</source>. <year>2017</year>;<volume>44</volume>:<fpage>708</fpage>‐<lpage>716</lpage>.<pub-id pub-id-type="pmid">28556062</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0038"><string-name><surname>Alkaya</surname><given-names>B</given-names></string-name>, <string-name><surname>Laleman</surname><given-names>I</given-names></string-name>, <string-name><surname>Keceli</surname><given-names>S</given-names></string-name>, <string-name><surname>Ozcelik</surname><given-names>O</given-names></string-name>, <string-name><surname>Cenk Haytac</surname><given-names>M</given-names></string-name>, <string-name><surname>Teughels</surname><given-names>W</given-names></string-name>. <article-title>Clinical effects of probiotics containing Bacillus species on gingivitis: a pilot randomized controlled trial</article-title>. <source>J Periodontal Res</source>. <year>2017</year>;<volume>52</volume>:<fpage>497</fpage>‐<lpage>504</lpage>.<pub-id pub-id-type="pmid">27859252</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0039">
                <label>39</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0039"><string-name><surname>Ng</surname><given-names>VW</given-names></string-name>, <string-name><surname>Bissada</surname><given-names>NF</given-names></string-name>. <article-title>Clinical evaluation of systemic doxycycline and ibuprofen administration as an adjunctive treatment for adult periodontitis</article-title>. <source>J Periodontol</source>. <year>1998</year>;<volume>69</volume>:<fpage>772</fpage>‐<lpage>776</lpage>.<pub-id pub-id-type="pmid">9706854</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0040">
                <label>40</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0040"><string-name><surname>Bartold</surname><given-names>PM</given-names></string-name>, <string-name><surname>du Bois</surname><given-names>AH</given-names></string-name>, <string-name><surname>Gannon</surname><given-names>S</given-names></string-name>, <string-name><surname>Haynes</surname><given-names>DR</given-names></string-name>, <string-name><surname>Hirsch</surname><given-names>RS</given-names></string-name>. <article-title>Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis</article-title>. <source>Inflammopharmacology</source>. <year>2013</year>;<volume>21</volume>:<fpage>321</fpage>‐<lpage>338</lpage>.<pub-id pub-id-type="pmid">23446952</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0041">
                <label>41</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0041"><string-name><surname>Zhang</surname><given-names>Z</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>Y</given-names></string-name>, <string-name><surname>Bian</surname><given-names>X</given-names></string-name>. <article-title>Clinical effect of azithromycin as an adjunct to non‐surgical treatment of chronic periodontitis: a meta‐analysis of randomized controlled clinical trials</article-title>. <source>J Periodontal Res</source>. <year>2016</year>;<volume>51</volume>:<fpage>275</fpage>‐<lpage>283</lpage>.<pub-id pub-id-type="pmid">26362529</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0042">
                <label>42</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0042"><string-name><surname>Ray</surname><given-names>WA</given-names></string-name>, <string-name><surname>Murray</surname><given-names>KT</given-names></string-name>, <string-name><surname>Hall</surname><given-names>K</given-names></string-name>, <string-name><surname>Arbogast</surname><given-names>PG</given-names></string-name>, <string-name><surname>Stein</surname><given-names>CM</given-names></string-name>. <article-title>Azithromycin and the risk of cardiovascular death</article-title>. <source>N Engl J Med</source>. <year>2012</year>;<volume>366</volume>:<fpage>1881</fpage>‐<lpage>1890</lpage>.<pub-id pub-id-type="pmid">22591294</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0043">
                <label>43</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0043"><string-name><surname>Elwakeel</surname><given-names>NM</given-names></string-name>, <string-name><surname>Hazaa</surname><given-names>HH</given-names></string-name>. <article-title>Effect of omega 3 fatty acids plus low‐dose aspirin on both clinical and biochemical profiles of patients with chronic periodontitis and type 2 diabetes: a randomized double blind placebo‐controlled study</article-title>. <source>J Periodontal Res</source>. <year>2015</year>;<volume>50</volume>:<fpage>721</fpage>‐<lpage>729</lpage>.<pub-id pub-id-type="pmid">25604769</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0044">
                <label>44</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0044"><string-name><surname>Keskiner</surname><given-names>I</given-names></string-name>, <string-name><surname>Saygun</surname><given-names>I</given-names></string-name>, <string-name><surname>Bal</surname><given-names>V</given-names></string-name>, <string-name><surname>Serdar</surname><given-names>M</given-names></string-name>, <string-name><surname>Kantarci</surname><given-names>A</given-names></string-name>. <article-title>Dietary supplementation with low‐dose omega‐3 fatty acids reduces salivary tumor necrosis factor‐alpha levels in patients with chronic periodontitis: a randomized controlled clinical study</article-title>. <source>J Periodontal Res</source>. <year>2017</year>;<volume>52</volume>:<fpage>695</fpage>‐<lpage>703</lpage>.<pub-id pub-id-type="pmid">28177133</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0045">
                <label>45</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0045"><string-name><surname>Castro Dos Santos</surname><given-names>NC</given-names></string-name>, <string-name><surname>Andere</surname><given-names>NM</given-names></string-name>, <string-name><surname>Araujo</surname><given-names>CF</given-names></string-name>, et al. <article-title>Omega‐3 PUFA and aspirin as adjuncts to periodontal debridement in patients with periodontitis and type 2 diabetes mellitus: randomized clinical trial</article-title>. <source>J Periodontol</source>. <year>2020</year>;<volume>91</volume>:<fpage>1318</fpage>‐<lpage>1327</lpage>.<pub-id pub-id-type="pmid">32103495</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0046">
                <label>46</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0046"><string-name><surname>Hsieh</surname><given-names>LT</given-names></string-name>, <string-name><surname>Nastase</surname><given-names>MV</given-names></string-name>, <string-name><surname>Zeng‐Brouwers</surname><given-names>J</given-names></string-name>, <string-name><surname>Iozzo</surname><given-names>RV</given-names></string-name>, <string-name><surname>Schaefer</surname><given-names>L</given-names></string-name>. <article-title>Soluble biglycan as a biomarker of inflammatory renal diseases</article-title>. <source>Int J Biochem Cell Biol</source>. <year>2014</year>;<volume>54</volume>:<fpage>223</fpage>‐<lpage>235</lpage>.<pub-id pub-id-type="pmid">25091702</pub-id></mixed-citation>
              </ref>
              <ref id="jper10747-bib-0047">
                <label>47</label>
                <mixed-citation publication-type="journal" id="jper10747-cit-0047"><string-name><surname>Polgar</surname><given-names>A</given-names></string-name>, <string-name><surname>Falus</surname><given-names>A</given-names></string-name>, <string-name><surname>Koo</surname><given-names>E</given-names></string-name>, et al. <article-title>Elevated levels of synovial fluid antibodies reactive with the small proteoglycans biglycan and decorin in patients with rheumatoid arthritis or other joint diseases</article-title>. <source>Rheumatology</source>. <year>2003</year>;<volume>42</volume>:<fpage>522</fpage>‐<lpage>527</lpage>.<pub-id pub-id-type="pmid">12649398</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
